Mirizzi Syndrome
Mirizzi syndrome is the extrinsic compression of the common hepatic duct by an impacted gallstone in the cystic duct or Hartmann's pouch, causing obstructive jaundice.
Mirizzi syndrome is defined as obstruction of the common hepatic duct (CHD) caused by extrinsic compression from an impacted gallstone in the cystic duct or Hartmann's pouch (infundibulum) of the gallbladder [1][2]. The name tells you the core pathology: a gallstone that's not inside the common bile duct (CBD), but beside it, pushing on it from the outside.
The key conceptual distinction: this is extrinsic compression — the stone is in the gallbladder/cystic duct, not in the CBD itself, yet it still causes obstructive jaundice. This is what makes it a diagnostic trap.
As chronic inflammation persists, the impacted stone can erode through the wall of the cystic duct/gallbladder into the adjacent bile duct, creating a cholecystobiliary fistula (an abnormal communication between gallbladder and the common hepatic duct or CBD) [1][2]. This fistula is the basis for the classification system and dictates surgical approach.
Courvoisier's Law Exception
Mirizzi syndrome is a classic exception to Courvoisier's Law [2]. Courvoisier's Law states that in painless jaundice with an enlarged gallbladder, the cause is unlikely to be gallstones (because a chronically stone-diseased gallbladder is fibrosed and cannot distend). However, in Mirizzi syndrome, the gallbladder may be palpable because the stone is impacted at the neck/cystic duct — the gallbladder body and fundus can still distend proximal to the impaction while simultaneously causing CHD obstruction. Students frequently forget this exception.
| Parameter | Detail |
|---|---|
| Incidence | 0.05–4% of patients undergoing surgery for cholelithiasis [1] |
| Sex | Female predominance: ~50–77% are female, reflecting the higher incidence of gallstones in women [1] |
| Age | Typically older adults (mean age 60–70 years) — correlates with long-standing gallstone disease |
| Geography | Found worldwide; follows the epidemiology of gallstone disease. In Hong Kong, cholelithiasis is common, and Mirizzi syndrome is an important differential for obstructive jaundice in the biliary surgical setting |
Why the female predominance? Because Mirizzi syndrome is a complication of gallstones, and gallstones are far more common in women — remember the 5Fs: Female, Fat, Forty, Fertile, Family history [1]. More gallstones → more chance of impaction at Hartmann's pouch → more Mirizzi syndrome.
3. Risk Factors
Since Mirizzi syndrome is fundamentally a complication of gallstone disease, the risk factors are those for cholelithiasis, plus anatomical factors that predispose to the specific impaction pattern:
- 5Fs: Female, Forty (middle age), Fat (obesity), Fertile (pregnancy/multiparity), Family history [1]
- Rapid weight loss (e.g., post-bariatric surgery) — increases biliary cholesterol saturation
- Diabetes mellitus
- Liver cirrhosis
- Haemolytic disorders (thalassaemia, hereditary spherocytosis, sickle cell disease) — excess bilirubin → pigment stones
- Drugs: oral contraceptives, estrogen replacement therapy — increase biliary cholesterol secretion
- Crohn's disease (terminal ileal disease → impaired bile salt reabsorption → altered bile composition)
- Total parenteral nutrition (TPN) — gallbladder stasis
- Low insertion of the cystic duct — when the cystic duct runs parallel to and closely alongside the CHD for a long distance, an impacted stone in the cystic duct is more likely to compress the CHD
- Long cystic duct running parallel to the CHD
- Large gallstones — stones > 1 cm are more likely to impact at Hartmann's pouch and are large enough to exert significant extrinsic compression
- Chronic cholecystitis with recurrent inflammation — leads to fibrosis and adhesions that "fix" the gallbladder to the bile duct, facilitating compression and eventual fistula formation
Why anatomy matters
The normal anatomy has the cystic duct joining the CHD at an angle. If anatomical variants cause the cystic duct and CHD to run in close parallel, even a modestly sized stone can compress the CHD. This is why Mirizzi syndrome is relatively rare — it requires the "perfect storm" of a large stone, impacted at exactly the right spot, in a patient with favourable (or rather unfavourable) anatomy.
4. Anatomy and Function
Understanding Mirizzi syndrome requires a solid grasp of biliary anatomy:
The gallbladder is a pear-shaped hollow organ on the inferior surface of the liver (segments IV and V). It has four anatomical parts [1]:
- Fundus — the blind end, projects beyond the inferior liver edge at the tip of the 9th costal cartilage (transpyloric plane landmark)
- Body — the main portion, lying in the gallbladder fossa
- Infundibulum (Hartmann's pouch) — a saccular outpouching at the junction of the body and neck; the convexity of the curved neck. This is where stones classically impact in Mirizzi syndrome [1][2]
- Neck — the narrow tapered portion leading to the cystic duct; contains the spiral valves of Heister
- The cystic duct (typically 2–4 cm long) connects the gallbladder neck to the common hepatic duct
- The CHD is formed by the confluence of the right and left hepatic ducts at the hilum (porta hepatis)
- The cystic duct joins the CHD (usually on its lateral aspect) to form the common bile duct (CBD)
- Calot's triangle (cystohepatic triangle): bounded by the cystic duct inferiorly, common hepatic duct medially, and inferior liver edge superiorly. Contains the cystic artery (branch of right hepatic artery) and the cystic lymph node (of Lund). This is the critical dissection zone in cholecystectomy — and in Mirizzi syndrome, it is obliterated by inflammation and fibrosis, making surgery treacherous.
The proximity of Hartmann's pouch/cystic duct to the common hepatic duct is the anatomical basis for Mirizzi syndrome. When a large stone impacts in this region, it compresses the CHD from the lateral or anterolateral aspect. The closer these structures are anatomically (particularly with a long parallel cystic duct), the easier it is for a stone to cause obstruction.
- The gallbladder concentrates and stores bile (up to 10-fold concentration) between meals
- Upon fatty meal ingestion → CCK release from duodenal I-cells → gallbladder contraction + sphincter of Oddi relaxation → bile ejection into duodenum
- In Mirizzi syndrome, gallbladder function is typically already impaired by chronic stone disease and inflammation
5. Etiology (Focused on Hong Kong Context)
| Stone Type | Composition | Associations | Relevance in HK |
|---|---|---|---|
| Cholesterol stones (most common in West and increasingly in HK) | > 50% cholesterol monohydrate crystals | Obesity, metabolic syndrome, 5Fs, supersaturated bile | Rising prevalence with Westernisation of diet |
| Brown pigment stones | Calcium bilirubinate + bacterial glycoproteins | Biliary stasis, bacterial infection (E. coli β-glucuronidase), parasitic infection | Particularly relevant in Hong Kong — associated with recurrent pyogenic cholangitis (RPC / "Hong Kong disease") [1] |
| Black pigment stones | Calcium bilirubinate + polymers | Haemolytic disorders, cirrhosis, TPN | Less common cause of Mirizzi |
In the Hong Kong context, recurrent pyogenic cholangitis (RPC) is an important associated condition. RPC (also called "Oriental cholangiohepatitis" or "Hong Kong disease") involves recurrent formation of brown pigment stones within intrahepatic ducts [1]. While RPC stones typically form within bile ducts (de novo), the chronic biliary inflammation and stone burden can contribute to gallbladder stone formation and, rarely, Mirizzi syndrome.
Parasitic infections relevant to Hong Kong and Southeast Asia that predispose to biliary stone disease include [1]:
- Clonorchis sinensis (Chinese liver fluke) — endemic in southern China, including Hong Kong
- Opisthorchis viverrini
- Ascaris lumbricoides
These parasites cause biliary inflammation, stasis, and serve as nidi for stone formation.
While classic Mirizzi syndrome is stone-related, extrinsic CHD compression can rarely be caused by:
- Gallbladder tumour (gallbladder carcinoma at the neck)
- Xanthogranulomatous cholecystitis
- Large parasitic cysts
6. Pathophysiology
This is the heart of understanding the condition. The pathophysiology proceeds in a stepwise fashion:
A large gallstone migrates into or forms within Hartmann's pouch or the proximal cystic duct. The stone becomes impacted — it cannot pass distally through the cystic duct (too large) and cannot fall back into the gallbladder body. This is the initiating event.
Why Hartmann's pouch? Because it is a natural "trap" — the pouch-like outpouching at the gallbladder neck creates a pocket where stones can lodge. The spiral valves of Heister in the cystic duct further prevent passage.
Due to the anatomical proximity of Hartmann's pouch/cystic duct to the CHD, the impacted stone exerts direct mechanical compression on the CHD from outside [1][2]. This causes:
- Partial or complete obstruction of bile flow through the CHD
- Dilatation of intrahepatic bile ducts proximal to the obstruction
- Normal-calibre CBD distal to the obstruction (below the level of cystic duct insertion)
This creates the characteristic imaging finding: dilated biliary system above the level of the gallbladder neck with an abrupt transition to normal-calibre CBD below [1].
The impacted stone and obstructed bile flow trigger:
- Local inflammatory response — pericholecystic inflammation, oedema, fibrosis
- Bile stasis proximal to obstruction → bacterial colonization → ascending cholangitis
- Recurrent episodes of cholangitis further exacerbate inflammation
Why does bile stasis predispose to infection? Normally, bile flow is sterile and the continuous antegrade flow "flushes" bacteria. When flow is obstructed, bacteria (normally present in small numbers from the duodenum via the sphincter of Oddi) multiply in the stagnant bile. The most common organisms are enteric Gram-negatives: E. coli, Klebsiella, and anaerobes [1].
With chronic inflammation and pressure necrosis, the impacted stone can:
- Erode through the wall of the cystic duct/gallbladder and the adjacent wall of the CHD/CBD
- Create an internal fistula between the gallbladder and the bile duct — the cholecystobiliary fistula (or "cholecystohepatic" / "cholecystocholedochal" fistula) [1][2]
Why does this happen? The stone sits pressed against the bile duct wall for weeks to months. Constant pressure + inflammatory mediators + ischaemia of the compressed wall → pressure necrosis → wall breakdown → fistula. This is the same mechanism by which a gallstone can erode into the duodenum (creating a cholecystoenteric fistula in gallstone ileus).
The extent of bile duct wall destruction determines the Csendes classification type (see below).
Once the fistula is established:
- Gallstones can migrate through the fistula into the CBD → choledocholithiasis
- Chronic inflammation + biliary stasis → predispose to gallbladder carcinoma [1][2]
- Cholecystoenteric fistula may also form (Type V) → gallstone ileus if stone passes into bowel [2]
Pathophysiology in One Sentence
A large stone impacts in Hartmann's pouch → compresses the CHD from outside → obstructive jaundice → chronic inflammation → pressure necrosis → cholecystobiliary fistula → stone migration, recurrent cholangitis, and cancer risk.
The Csendes classification (1989, updated by Csendes and Beltran 2008) is the standard classification system. It is based on the presence, size, and extent of the cholecystobiliary fistula, which directly determines the surgical approach [1][2].
| Type | Fistula | Description | Frequency | Surgical Implication |
|---|---|---|---|---|
| Type I | ❌ No fistula | Extrinsic compression of CHD by impacted stone in cystic duct / Hartmann's pouch. Bile duct wall is intact. | ~11% [1] | Cholecystectomy (laparoscopic or open). ECBD usually NOT required [1]. |
| Type II | ✅ Present | Cholecystobiliary fistula involving < 1/3 of the circumference of the CBD wall | ~41% [1] | Cholecystectomy + closure of fistula (suture repair / T-tube / choledochoplasty with gallbladder remnant) [1] |
| Type III | ✅ Present | Fistula involving 1/3 to 2/3 of the circumference of the CBD wall | ~44% [1] | Cholecystectomy OR bilioenteric anastomosis (choledochoduodenostomy / choledochojejunostomy). Suture of fistula NOT required [1]. |
| Type IV | ✅ Present | Fistula involving > 2/3 of the circumference (i.e., complete destruction of the CBD wall) | ~4% [1] | Bilioenteric anastomosis — typically Roux-en-Y choledochojejunostomy (entire CBD wall destroyed, cannot be primarily repaired) [1] |
| Type V | Any of above + cholecystoenteric fistula | 5A: without gallstone ileus; 5B: with gallstone ileus [2] | — | Address bowel obstruction (enterolithotomy for ileus) + manage biliary fistula per type |
Why does the classification matter?
The extent of bile duct wall destruction dictates whether you can simply close the hole (Types II–III), or whether the entire duct is so destroyed that you need to bypass it entirely with a bilioenteric anastomosis (Type IV). A surgeon who doesn't know the Csendes type preoperatively may get a very unpleasant surprise intraoperatively.
Type V — Added Later
The original Csendes classification (1989) had Types I–IV. Type V was added by Csendes and Beltran in 2008 to account for cases where a cholecystoenteric fistula coexists — this acknowledges the association between Mirizzi syndrome and gallstone ileus [2]. Subtypes 5A (no ileus) and 5B (gallstone ileus) are clinically important because gallstone ileus is a surgical emergency.
8. Clinical Features
Mirizzi syndrome has a variable clinical presentation [2], which is one reason it is frequently diagnosed late (often intraoperatively). The presentation depends on whether the patient has acute cholecystitis, cholangitis, or chronic biliary symptoms.
| Symptom | Pathophysiological Basis |
|---|---|
| Jaundice (most common presenting feature, ~60–100%) [1][2] | Extrinsic compression of the CHD by the impacted stone → bile cannot flow from the liver to the duodenum → conjugated bilirubin accumulates in the blood → deposits in skin and sclera. This is an obstructive (post-hepatic) jaundice with conjugated hyperbilirubinaemia. |
| Right upper quadrant (RUQ) pain [1][2] | (i) The impacted stone in Hartmann's pouch causes gallbladder distension and inflammation → visceral pain referred to the epigastrium/RUQ. (ii) Pericholecystic inflammation involves the parietal peritoneum → localised somatic RUQ pain. (iii) May also reflect concurrent acute cholecystitis. |
| Fever (with or without rigors) [1][2] | Bile stasis → bacterial infection → ascending cholangitis (Charcot's triad: fever, jaundice, RUQ pain). Fever reflects systemic inflammatory response to bacteraemia. Rigors suggest Gram-negative bacteraemia with endotoxin release. |
| Tea-coloured (dark) urine [3] | Conjugated bilirubin is water-soluble → filtered by the kidneys → excreted in urine → dark "tea-coloured" or "cola-coloured" urine. |
| Pale (clay-coloured) stools [3] | Obstruction prevents conjugated bilirubin from reaching the duodenum → no conversion to stercobilinogen/stercobilin → stools lose their brown colour. |
| Pruritus | Retained bile salts deposit in the skin → stimulate cutaneous nerve endings → itching. The exact mechanism is debated (may involve lysophosphatidic acid and autotaxin rather than bile salts directly), but the association with obstructive jaundice is well-established. |
| Nausea and vomiting | Vagal-mediated reflex from gallbladder/biliary distension. Also exacerbated by concurrent pancreatitis if present. |
| Weight loss / anorexia | Chronic illness, recurrent biliary infections, and malabsorption of fats (due to reduced bile reaching the duodenum). Also raises concern for concurrent gallbladder carcinoma [1][2]. |
Charcot's Triad in Mirizzi Syndrome
Up to 1/3 of patients present with features of acute cholecystitis [1], and many others present with Charcot's triad (fever + jaundice + RUQ pain) — indistinguishable from acute cholangitis from other causes. This is why Mirizzi syndrome is classically a preoperative or intraoperative surprise.
| Sign | Pathophysiological Basis |
|---|---|
| Jaundice (scleral icterus, skin yellowing) | Conjugated hyperbilirubinaemia (clinically detectable when bilirubin > 50 µmol/L [3]). The sclerae are affected first because of high elastin content with affinity for bilirubin. |
| RUQ tenderness | Inflammation of the gallbladder and pericholecystic tissues → peritoneal irritation → localised tenderness. |
| Murphy's sign (positive in concurrent acute cholecystitis) | During deep palpation of the RUQ, the inflamed gallbladder descends with inspiration and contacts the examiner's hand → sharp pain causes inspiratory arrest. Indicates parietal peritoneal involvement by the inflamed gallbladder. |
| Palpable gallbladder [2] | The stone is impacted at the gallbladder neck/cystic duct — the body and fundus of the gallbladder proximal to the obstruction can distend (with bile/mucus/pus). This is the basis for Mirizzi syndrome being an exception to Courvoisier's Law [2]. |
| Hepatomegaly (mild) | Biliary obstruction → back-pressure on intrahepatic ducts → mild hepatic congestion and swelling. |
| Fever with tachycardia | Systemic inflammatory response to cholangitis/cholecystitis. If persistent high fever with hypotension (Reynolds' pentad: Charcot's triad + altered mental status + hypotension), suggests suppurative cholangitis — a surgical emergency. |
| Excoriations (scratch marks) | Secondary to pruritus from bile salt deposition in skin. |
| Bleeding tendency (ecchymoses, prolonged bleeding) [3] | Obstructive jaundice → reduced bile salts in gut → impaired absorption of fat-soluble vitamins (A, D, E, K) → Vitamin K deficiency → reduced synthesis of clotting factors II, VII, IX, X → coagulopathy [3]. |
Up to 1/3 of patients with Mirizzi syndrome present with concurrent acute cholecystitis [1], and in rare cases, acute pancreatitis [1] (if a stone also obstructs the pancreatic duct or ampulla).
There is an important association with gallbladder cancer [1][2][3]:
- The chronic inflammation, biliary stasis, and repeated mucosal injury predispose to dysplasia-carcinoma sequence
- Incidence of concurrent gallbladder carcinoma in Mirizzi syndrome is reported as 5–28% in various series
- This is why CT abdomen with contrast should be performed to look for enlarged porta hepatis lymph nodes or hepatic infiltration of metastasis [1]
Mirizzi Syndrome and Gallbladder Cancer
Always think about concurrent gallbladder carcinoma when you diagnose Mirizzi syndrome. The chronic inflammation is a risk factor for malignant transformation. This is also why intraoperative frozen section of the gallbladder specimen should be considered, and why CT is essential in the workup — you need to rule out malignancy before planning surgery [1][3].
These are the systemic effects of biliary obstruction that apply to any cause of obstructive jaundice but are directly relevant to Mirizzi syndrome management [3]:
| Consequence | Mechanism |
|---|---|
| Bleeding tendency [3] | Bile salt deficiency → malabsorption of fat-soluble vitamin K → ↓ hepatic synthesis of factors II, VII, IX, X |
| Infection / biliary sepsis [3] | (i) Endotoxaemia — obstructed liver cannot clear gut-derived endotoxins via portal circulation. (ii) Impaired reticuloendothelial (Kupffer cell) function. (iii) Impaired cell-mediated immunity. |
| Poor wound healing / poor anastomotic healing [3] | Impaired hepatic protein synthesis (albumin, pre-albumin) in the setting of biliary obstruction and chronic inflammation → poor nutritional status → poor tissue repair. |
| Renal impairment (hepatorenal syndrome) | Cholestasis → impaired renal perfusion via systemic vasodilation and endotoxin-mediated renal vasoconstriction. |
Preoperative Correction
Before operating on Mirizzi syndrome with obstructive jaundice, you must correct coagulopathy (give Vitamin K IM/IV at least 24–48 hours preoperatively), optimise nutrition, and ensure adequate hydration to protect the kidneys. Biliary decompression (via ERCP stenting) may be performed preoperatively to reduce bilirubin and improve hepatic function before definitive surgery [1][2].
Before diving into investigations (which will be covered in the next section), the clinical approach to a suspected Mirizzi syndrome patient follows this logic:
- Suspect it when you see obstructive jaundice + gallstones + features that don't quite fit choledocholithiasis (e.g., imaging shows dilated intrahepatic ducts but no stone in the CBD, or a contracted/inflamed gallbladder with stone at the neck)
- Assess severity: Is there cholangitis? (Charcot's/Reynolds') → this determines urgency of biliary decompression
- Rule out malignancy: The overlap between Mirizzi syndrome and gallbladder cancer / cholangiocarcinoma is significant — CT is essential
- Classify: The Csendes type determines the surgical approach — this is usually determined by ERCP and/or intraoperative findings
High Yield: Mirizzi syndrome is a "great mimicker" — it can present like acute cholecystitis, acute cholangitis, choledocholithiasis, or even biliary malignancy. The diagnosis is often made intraoperatively. Preoperative recognition is critical because it changes the surgical plan and reduces the risk of bile duct injury during cholecystectomy.
High Yield Summary
Definition: CHD obstruction by extrinsic compression from a stone impacted in Hartmann's pouch / cystic duct ± cholecystobiliary fistula.
Epidemiology: 0.05–4% of patients undergoing cholecystectomy; F > M (reflects gallstone epidemiology).
Risk factors: Same as gallstones (5Fs) + anatomical factors (low cystic duct insertion, long parallel cystic duct, large stones).
Key anatomy: Hartmann's pouch (infundibulum) sits adjacent to the CHD — the proximity is the anatomical basis for extrinsic compression.
Pathophysiology sequence: Large stone impacts in Hartmann's pouch → extrinsic CHD compression → obstructive jaundice + bile stasis → chronic inflammation → pressure necrosis of bile duct wall → cholecystobiliary fistula (Types II–IV) → ± cholecystoenteric fistula (Type V).
Csendes classification: Type I (no fistula), Type II ( < 1/3 CBD wall), Type III (1/3–2/3), Type IV ( > 2/3 / complete destruction), Type V (any + cholecystoenteric fistula ± gallstone ileus).
Clinical features: Jaundice + RUQ pain + fever (Charcot's triad); exception to Courvoisier's Law (palpable GB with jaundice from stones); tea-coloured urine, pale stools, pruritus.
Associations: Gallbladder carcinoma (5–28%), gallstone ileus (Type V), concurrent acute cholecystitis (1/3 of cases).
Systemic effects of obstruction: Bleeding tendency (Vit K malabsorption), biliary sepsis (impaired Kupffer cell function), poor wound healing (impaired protein synthesis).
Active Recall - Mirizzi Syndrome (Definition, Epidemiology, Pathophysiology, Classification, Clinical Features)
[1] Senior notes: felixlai.md (Mirizzi syndrome, pp. 572–575; Cholelithiasis, p. 508; Gallbladder cancer etiology, p. 563; Obstructive jaundice, pp. 500–501; Recurrent pyogenic cholangitis, p. 526) [2] Senior notes: maxim.md (Mirizzi syndrome, pp. 130–132; Courvoisier's Law, p. 130; Gallstone ileus, p. 132; Obstructive jaundice, p. 251) [3] Lecture slides: Malignant biliary obstruction.pdf (Manifestations of pathophysiological disturbance of MBO: bleeding tendency, infection, poor wound healing)
Differential Diagnosis of Mirizzi Syndrome
The fundamental difficulty with Mirizzi syndrome is that it presents as obstructive jaundice ± cholangitis ± cholecystitis — a constellation shared by many hepatobiliary conditions. The stone is not in the CBD (where you'd expect it in choledocholithiasis), but its effects mimic a CBD stone. Additionally, the pericholecystic inflammation can mimic a hilar mass (gallbladder carcinoma, Klatskin tumour). This is why Mirizzi syndrome is frequently diagnosed only intraoperatively [1].
The DDx can be approached systematically by:
- Level of biliary obstruction (hilar vs. mid-CBD vs. distal CBD) [3]
- Mechanism of obstruction (intraluminal vs. mural vs. extramural) [4]
- Clinical presentation pattern (cholangitis-predominant vs. cholecystitis-predominant vs. painless jaundice)
Mirizzi syndrome causes obstruction at the hilum / proximal CHD level — the stone in Hartmann's pouch compresses the CHD just below the hepatic confluence. This means the DDx is primarily against other causes of hilar-level obstruction [1][3].
Causes according to level of obstruction [3]:
| Level | Differential Diagnoses | Key Distinguishing Features from Mirizzi |
|---|---|---|
| Hilum (where Mirizzi acts) | CA Gallbladder, HCC, Klatskin's tumour (hilar cholangiocarcinoma), Mirizzi syndrome, Porta lymphadenopathy, Primary sclerosing cholangitis (PSC), Recurrent pyogenic cholangitis (RPC) [3] | See individual entries below |
| Mid-CBD | CA CBD, CA Head of pancreas, Lymphadenopathy [3] | Stone in Mirizzi is at GB neck/cystic duct level, not mid-CBD; imaging shows stone at GB neck rather than within CBD lumen |
| Distal CBD | Bile duct strictures, Periampullary carcinoma, Choledochal cysts, Pancreatic cysts, Chronic pancreatitis [3] | Distal CBD obstruction shows different dilatation pattern (dilated CBD + CHD); Mirizzi shows normal-calibre CBD below obstruction |
Differential diagnosis of obstructive jaundice [4]:
| Mechanism | Conditions | Explanation |
|---|---|---|
| Intraluminal | Choledocholithiasis, Acute cholangitis, RPC [4] | Stone is inside the CBD lumen, not compressing from outside |
| Mural | Cholangiocarcinoma, PSC [4] | Pathology is in the bile duct wall itself (tumour or fibrosis) |
| Extramural | CA head of pancreas, Lymphadenopathy, Gallstone (Mirizzi syndrome) [4] | Mirizzi is classified as extramural — the stone is outside the bile duct compressing it |
Mirizzi is Extramural Obstruction
This is a key conceptual point: even though Mirizzi syndrome is caused by a gallstone (which you'd normally associate with intraluminal obstruction), the stone is in the cystic duct/Hartmann's pouch, not inside the CBD. It compresses the CHD from outside — hence it is classified as extramural obstruction [4]. This is the same category as a pancreatic head mass compressing the CBD. Understanding this helps you see why imaging may not show a stone within the CBD.
Approach 3: Individual Differential Diagnoses with Distinguishing Features
These are the key conditions listed in the senior notes that must be systematically differentiated from Mirizzi syndrome [1]:
The most important differential — and the condition Mirizzi syndrome is most frequently confused with.
- Mechanism: Gallstone migrates from gallbladder through cystic duct and lodges within the CBD lumen [2][5]
- Why it mimics Mirizzi: Both cause obstructive jaundice, RUQ pain, and cholestatic LFTs. Both are stone-related. Both may present with Charcot's triad if complicated by cholangitis.
- How to distinguish:
| Feature | Choledocholithiasis | Mirizzi Syndrome |
|---|---|---|
| Stone location | Within CBD lumen | In Hartmann's pouch / cystic duct (outside CBD) |
| CBD calibre | Dilated CBD with stone visible within it on USG [5] | Normal-calibre CBD below the level of obstruction; dilatation is above GB neck level only [1] |
| USG finding | Dilated CBD ( > 8 mm) ± visible stone in CBD | Contracted/inflamed GB with stone at neck; dilated biliary system above GB neck with abrupt transition to normal CBD below [1] |
| ERCP finding | Stone within CBD lumen | Eccentric/excavating defect on lateral wall of CBD at level of cystic duct; ± contrast passing into GB via fistula [1] |
| Gallbladder | Usually contains stones but may not be inflamed | Typically contracted and inflamed, often with a large stone impacted at neck |
The Key USG Clue
The single most helpful USG finding that points to Mirizzi over choledocholithiasis is: dilated intrahepatic ducts + stone at GB neck + normal-calibre CBD distal to the stone [1]. In choledocholithiasis, the CBD itself is dilated and you may see the stone within it.
- Mechanism: Prolonged gallstone impaction at Hartmann's pouch/cystic duct → gallbladder distension → chemical then bacterial inflammation [6][7]
- Why it mimics Mirizzi: Both involve stone impaction at the same anatomical site (Hartmann's pouch/cystic duct). Both cause RUQ pain, fever, positive Murphy's sign. In fact, up to 1/3 of Mirizzi syndrome patients present with acute cholecystitis [1].
- How to distinguish:
| Feature | Acute Cholecystitis | Mirizzi Syndrome |
|---|---|---|
| Jaundice | Usually absent or mild (bilirubin only mildly elevated from pericholecystic inflammation) [8] | Prominent jaundice — because CHD is obstructed, not just cystic duct [1] |
| LFT | Usually normal or mildly abnormal [8] | Significantly elevated ALP and bilirubin (cholestatic pattern) [1] |
| Intrahepatic duct dilatation | Absent (obstruction limited to gallbladder outflow) | Present (CHD obstruction causes upstream dilatation) |
| CBD calibre | Normal | Normal below stone, but dilated CHD above |
Clinical pearl: If you see a patient with what looks like acute cholecystitis but with disproportionately significant jaundice and dilated intrahepatic ducts, think Mirizzi syndrome. "Severe jaundice is suggestive of cholangitis, CBD obstruction or obstruction of the bile ducts by severe pericholecystic inflammation or Mirizzi syndrome" [8].
- Mechanism: Malignant neoplasm of the gallbladder (90% adenocarcinoma), often arising in a background of chronic cholecystitis/cholelithiasis [9]
- Why it mimics Mirizzi: Both can present with obstructive jaundice at the hilar level [3]. Both are associated with gallstones. The inflammatory mass in Mirizzi can look exactly like a gallbladder tumour on imaging. Critically, Mirizzi syndrome itself is a risk factor for gallbladder carcinoma — the two can coexist [1][2].
- How to distinguish:
| Feature | CA Gallbladder | Mirizzi Syndrome |
|---|---|---|
| Jaundice character | Painless progressive obstructive jaundice (late stage) [4] | Painful jaundice with cholangitis/cholecystitis features |
| Constitutional symptoms | Weight loss, anorexia, cachexia (more prominent) | Less prominent unless concurrent malignancy |
| Imaging | CT: enhancing mass lesion, porta hepatis lymphadenopathy, liver infiltration (segments IV/V) [1][9] | MRCP: T2-weighted images can differentiate inflammatory from neoplastic mass [1]; CT shows no enhancing mass |
| Gallbladder wall | Irregular thickening or mass, loss of GB-liver interface | Diffuse thickening (inflammatory), preserved interface |
| Histology | Malignant cells on biopsy/frozen section | Inflammatory changes |
Always Rule Out CA Gallbladder
CT abdomen should be performed in all suspected Mirizzi syndrome to determine whether malignancy is present by demonstrating enlarged porta hepatis LNs or hepatic infiltration/metastasis [1]. This is non-negotiable. The 5–28% coexistence rate of gallbladder cancer with Mirizzi syndrome means you cannot assume it is "just" Mirizzi.
- Mechanism: Cholangiocarcinoma (adenocarcinoma, > 90%) arising at the confluence of the hepatic ducts — "Klatskin" = perihilar cholangiocarcinoma [3][10]
- Why it mimics Mirizzi: Both cause hilar-level obstruction with intrahepatic duct dilatation. Both cause obstructive jaundice.
- How to distinguish:
| Feature | Klatskin's Tumour | Mirizzi Syndrome |
|---|---|---|
| Pain | Often painless progressive jaundice [4] | Typically painful (cholecystitis/cholangitis) |
| Gallstones | Usually absent | Present (the cause) |
| MRCP/ERCP | Stricture/occlusion at the hepatic duct confluence; no gallstone at GB neck | Stone at GB neck; extrinsic compression of CHD |
| CT | Enhancing hilar mass, biliary dilatation above confluence, vascular encasement | Inflammatory changes at GB neck, no true mass |
| Risk factors | PSC, RPC, choledochal cysts, Caroli's disease, parasites [10] | Gallstones (5Fs) |
- Mechanism: Recurrent cholangitis from de novo intrahepatic pigment stone formation → stricturing and dilatation of the intrahepatic biliary tree [11]
- Why it mimics Mirizzi: Both cause cholangitis (Charcot's triad), both involve stones, and RPC is also an exception to Courvoisier's Law [2]. Both are common in the Hong Kong population.
- How to distinguish:
| Feature | RPC | Mirizzi Syndrome |
|---|---|---|
| Stone type | Brown pigment / calcium bilirubinate stones formed de novo in intrahepatic ducts [11] | Usually cholesterol stones formed in gallbladder |
| Stone location | Intrahepatic ducts primarily [11] | Hartmann's pouch / cystic duct |
| Imaging | Disproportionate dilatation of intrahepatic ducts (especially left lobe) with intrahepatic stones and strictures [11] | Dilated ducts above GB neck with stone at GB neck; no intrahepatic stones |
| Epidemiology | Southeast Asia ("Hong Kong disease"), equal M:F, peak 30–40s [11] | Follows gallstone epidemiology (F > M) |
| Parasitic association | Clonorchis sinensis, Ascaris lumbricoides [11] | Not directly parasitic |
- Mechanism: Pyogenic (usually from biliary source or portal pyaemia) or amoebic abscess
- Why it mimics Mirizzi: Both cause fever, RUQ pain, and leukocytosis. A large abscess near the porta hepatis could compress the bile ducts.
- How to distinguish: USG/CT shows a fluid collection within the liver parenchyma (not a stone at GB neck). No intrahepatic duct dilatation pattern characteristic of biliary obstruction unless the abscess itself compresses ducts. Blood cultures/aspirate culture positive for organisms.
- Mechanism: Congenital dilatation of biliary tree → bile stasis → infection [12]
- Why it mimics Mirizzi: Both cause RUQ pain, jaundice, and fever. Choledochal cysts can present with a palpable mass.
- How to distinguish: Diagnosed predominantly before age 10 (60%) [12]. USG/MRCP shows a cystic dilatation of the bile duct rather than a stone at GB neck. Classic triad of RUQ mass + pain + jaundice (though only present in minority of adults).
- Mechanism: Premature activation of pancreatic enzymes → autodigestion [13]
- Why it mimics Mirizzi: Both can be caused by gallstones. Both cause RUQ/epigastric pain. Both elevate LFTs.
- How to distinguish: Pain in pancreatitis radiates to the back and is relieved by sitting up/leaning forward [13]. Markedly elevated serum amylase/lipase ( > 3× upper limit of normal). Pancreatic inflammation on CT. In Mirizzi, amylase may be mildly elevated but not to the degree seen in pancreatitis.
- Mechanism: Appendiceal luminal obstruction → distension → ischaemia → bacterial infection [1]
- Why it is listed: Both cause acute abdominal pain with fever and leukocytosis. However, appendicitis typically presents with periumbilical pain migrating to RIF (McBurney's point), not RUQ. Jaundice is absent. Listed as a DDx primarily because of the overlap in the "acute abdomen with fever and leucocytosis" category.
- Mechanism: Chronic progressive inflammation, fibrosis, and stricturing of both intra- and extrahepatic bile ducts of unknown aetiology [14]
- Why it mimics Mirizzi: Both can cause obstructive jaundice at the hilar level [3]. Both can cause cholangitis.
- How to distinguish: PSC has a strong association with ulcerative colitis [14]. Cholangiogram (MRCP/ERCP) shows "beaded" pattern of multifocal strictures alternating with dilatation throughout the biliary tree — very different from the focal hilar obstruction of Mirizzi. p-ANCA positive in ~80%. No gallstone at GB neck.
- Mechanism: Post-surgical or post-traumatic disruption of bile duct integrity
- Why it mimics Mirizzi: Both can cause jaundice and biliary collections. However, biliary leaks present in the post-operative context. HIDA scan or ERCP demonstrates active extravasation of bile.
In the history, differentiate stone vs tumour [4]:
| Feature | Stone (including Mirizzi) | Tumour (malignant biliary obstruction) |
|---|---|---|
| Pain | Painful (biliary colic, cholangitis) | Often painless (especially pancreatic head CA) |
| Jaundice pattern | Intermittent/fluctuating | Progressive |
| Fever | Common (cholangitis) | Less common unless secondary infection |
| Stool/urine | Tea-coloured urine, pale stool [4] | Same pattern |
| Weight loss | Less prominent | Significant |
| History of gallstones | Usually present | May be absent |
| Age | Any age (F > M) | Elderly (consider painless progressive obstructive jaundice in elderly = malignant until proven otherwise [4]) |
| Courvoisier's sign | Usually negative (exception: Mirizzi, double impaction, RPC) [2] | Usually positive |
| Differential | Key Distinguishing Feature from Mirizzi | Investigation That Clinches It |
|---|---|---|
| Choledocholithiasis | Stone within CBD; dilated CBD | USG/MRCP: stone in CBD lumen |
| Acute cholecystitis | Jaundice absent/mild; LFT normal/mild; no intrahepatic duct dilatation | USG: 5 cardinal signs; no duct dilatation |
| CA Gallbladder | Painless progressive jaundice; enhancing mass; LN; liver infiltration | CT + biopsy/frozen section |
| Klatskin's tumour | Painless jaundice; stricture at hepatic confluence; no gallstone | MRCP/ERCP: hilar stricture pattern |
| RPC | Intrahepatic pigment stones; left lobe predominance; SE Asian | MRCP: intrahepatic stones + strictures |
| Liver abscess | Fluid collection in liver parenchyma; no biliary duct stone | USG/CT: abscess cavity |
| Infected choledochal cyst | Cystic dilatation of bile duct; paediatric | MRCP: cyst morphology |
| Acute pancreatitis | Back-radiating pain; amylase/lipase > 3× ULN | Lipase + CT severity |
| Acute appendicitis | RIF pain; no jaundice | Clinical + CT |
| PSC | Beaded biliary strictures; UC association; p-ANCA+ | MRCP: multifocal strictures |
| Biliary leak | Post-surgical context | HIDA/ERCP: active extravasation |
High Yield Summary
Mirizzi syndrome DDx — key principles:
-
Mirizzi is an extramural cause of obstructive jaundice — classified with pancreatic head CA and lymphadenopathy, NOT with intraluminal stones [4]
-
Most commonly confused with choledocholithiasis — the key USG differentiator is: in Mirizzi, intrahepatic ducts are dilated but CBD is normal-calibre below the GB neck; in choledocholithiasis, the CBD itself is dilated [1]
-
Acute cholecystitis with disproportionate jaundice should trigger suspicion for Mirizzi [8]
-
Always rule out CA gallbladder with CT (5–28% coexistence rate) and MRCP (T2 differentiates inflammatory from neoplastic mass) [1]
-
Listed DDx from senior notes [1]: Choledocholithiasis, Acute cholecystitis, Liver abscess, Infected choledochal cysts, Biliary leaks, Acute pancreatitis, Acute appendicitis, RPC
-
In Hong Kong, RPC and parasitic-related biliary disease are particularly important differentials [11]
-
Painless progressive obstructive jaundice in elderly = malignant biliary obstruction until proven otherwise [4]
Active Recall - Mirizzi Syndrome Differential Diagnosis
References
[1] Senior notes: felixlai.md (Mirizzi syndrome DDx and diagnosis, pp. 572–574; Cholecystitis and Mirizzi, p. 556) [2] Senior notes: maxim.md (Mirizzi syndrome, pp. 130–132; Courvoisier's Law and exceptions, p. 130) [3] Senior notes: felixlai.md (Causes of obstructive jaundice by level of obstruction, p. 500) [4] Senior notes: maxim.md (Obstructive jaundice DDx and approach, p. 251) [5] Senior notes: maxim.md (Choledocholithiasis, p. 136) [6] Senior notes: maxim.md (Acute calculous cholecystitis, p. 131) [7] Senior notes: felixlai.md (Cholecystitis overview, p. 553) [8] Senior notes: felixlai.md (Acute cholecystitis physical examination — jaundice and Mirizzi, p. 556) [9] Senior notes: maxim.md (Gallbladder carcinoma, pp. 138–139) [10] Senior notes: maxim.md (Cholangiocarcinoma classification and risk factors, pp. 139–140) [11] Senior notes: felixlai.md (Recurrent pyogenic cholangitis, pp. 526–527); Senior notes: maxim.md (RPC, p. 136) [12] Senior notes: maxim.md (Choledochal cyst, p. 138) [13] Senior notes: felixlai.md (Acute pancreatitis, pp. 579–580) [14] Senior notes: felixlai.md (Primary sclerosing cholangitis, p. 529)
Diagnostic Criteria for Mirizzi Syndrome
Unlike acute cholecystitis (Tokyo Guidelines 2018) or acute cholangitis (Tokyo Guidelines 2018), there is no universally accepted set of formal diagnostic criteria for Mirizzi syndrome. The diagnosis is made by combining clinical suspicion with imaging findings. In fact, the majority of cases are diagnosed intraoperatively — only about 8–27% of cases are diagnosed preoperatively [1][2].
This is because:
- The clinical presentation is non-specific — it overlaps with cholecystitis, choledocholithiasis, and cholangitis
- The pathognomonic finding (stone at GB neck compressing CHD ± cholecystobiliary fistula) requires high-quality imaging to detect
- The dense pericholecystic inflammation makes anatomical delineation difficult even on cross-sectional imaging
Practical Diagnostic Approach
In practice, you suspect Mirizzi syndrome when a patient with gallstones has features of obstructive jaundice and imaging shows dilated intrahepatic ducts with a stone at the GB neck but a normal-calibre CBD below. You confirm it with MRCP and/or ERCP. The Csendes type (presence and extent of cholecystobiliary fistula) is often only definitively determined at ERCP or intraoperatively.
While no formal criteria exist, the diagnosis rests on demonstrating the following:
| Component | What You Need to Show |
|---|---|
| 1. Gallstone impaction | Stone impacted in Hartmann's pouch or cystic duct [1][2] |
| 2. CHD obstruction | Evidence of biliary obstruction at the level of the GB neck — dilated intrahepatic ducts above, normal CBD below [1] |
| 3. Exclusion of other causes | No stone in CBD lumen; no hilar mass; no malignancy on CT [1][2] |
| 4. Fistula assessment | Presence and extent of cholecystobiliary fistula (determines Csendes type) — usually by ERCP or intraoperative findings [1][2] |
When the patient also presents with features of acute cholangitis, the Tokyo Guidelines 2018 (TG18) criteria for cholangitis apply in parallel [7]:
Suspected cholangitis: ONE systemic inflammation criterion (fever/rigors OR abnormal WBC/CRP) AND ONE cholestasis criterion (jaundice OR abnormal LFTs)
Definite cholangitis: Suspected criteria met PLUS biliary dilatation on imaging AND evidence of aetiology (stone, stricture, stent) on imaging [7]
When the patient presents with features of acute cholecystitis, the Tokyo Guidelines 2018 (TG18) criteria for cholecystitis apply [8]:
- A: Local signs (Murphy's sign, RUQ mass/pain/tenderness)
- B: Systemic signs (fever, leukocytosis, elevated CRP)
- C: Imaging findings characteristic of acute cholecystitis
- Suspected = A + B; Definite = A + B + C [8]
The diagnostic workup for suspected Mirizzi syndrome follows a logical stepwise approach: Bloods → USG → CT → MRCP → ERCP. Each modality answers a specific question:
| Step | Modality | Question It Answers |
|---|---|---|
| 1 | Blood tests | Is there obstruction? Infection? Coagulopathy? |
| 2 | USG abdomen | Is there a stone at GB neck? Are intrahepatic ducts dilated? What is CBD calibre? |
| 3 | CT abdomen + contrast | Is there malignancy? Lymphadenopathy? Liver metastases? |
| 4 | MRCP | What is the precise biliary anatomy? Is it inflammatory or neoplastic? |
| 5 | ERCP | Is there a cholecystobiliary fistula? Can we decompress the biliary tree? |
Mermaid Diagnostic Algorithm
Investigation Modalities: Detailed Findings and Interpretation
1. Blood Tests (Laboratory Investigations)
Blood tests do not diagnose Mirizzi syndrome per se, but they characterise the degree of obstruction, infection, and fitness for intervention.
- Expected finding: Leukocytosis [1]
- Why: Leukocytosis (↑ WBC with neutrophil predominance and left shift / band forms) indicates an acute inflammatory/infectious process — present in concurrent acute cholecystitis, cholangitis, or pancreatitis [1]
- Interpretation:
- Mild leukocytosis (12,000–15,000/µL) → uncomplicated cholecystitis
- Marked leukocytosis ( > 20,000/µL) → suggests complicated disease (empyema, gangrenous cholecystitis, or suppurative cholangitis) [8]
- Also check: Thrombocytopenia — relevant when planning invasive procedures such as ERCP (need adequate platelets for sphincterotomy) [3][15]
- In patients with underlying cirrhosis: pancytopenia from hypersplenism may be present [15]
- Expected finding: ↑ ALP and bilirubin [1] — the classic cholestatic pattern
- Why: CHD obstruction prevents bile from draining into the duodenum
- ↑ Conjugated bilirubin: bile cannot flow → backs up into blood → conjugated (water-soluble) bilirubin spills into circulation
- ↑ ALP (alkaline phosphatase): ALP is concentrated in bile duct epithelium. Obstruction → back-pressure → induction of ALP synthesis + leakage into blood. The biliary isoenzyme is predominant.
- ↑ GGT (gamma-glutamyl transferase): rises in parallel with ALP in cholestasis; confirms biliary origin of ALP elevation [3][15]
- Transaminases (AST/ALT): may be mildly elevated (back-pressure hepatocyte injury) but typically NOT dramatically elevated unless acute biliary obstruction with "transaminitis" from sudden complete obstruction
Cholestatic Pattern = Think Obstruction
The cholestatic LFT pattern (ALP and GGT disproportionately elevated relative to transaminases, with raised conjugated bilirubin) points to biliary obstruction. This is different from the hepatocellular pattern (transaminases disproportionately elevated) seen in hepatitis. Always fractionate the bilirubin — in Mirizzi, it is primarily conjugated [7].
- Expected finding: Prolonged PT/INR in prolonged obstruction [3][15]
- Why: Obstructive jaundice → no bile salts reaching the gut → impaired absorption of fat-soluble vitamin K → vitamin K is a cofactor for hepatic γ-carboxylation of clotting factors II, VII, IX, X → coagulopathy [3]
- Clinical importance: Must be corrected before any invasive procedure. Give Vitamin K 10 mg IV/IM at least 24–48 hours before surgery or ERCP. If urgent, give Fresh Frozen Plasma (FFP) for immediate correction [3]
- Diagnostic value: If PT corrects with vitamin K → the liver is still functional (just vitamin K deficient). If PT does NOT correct → hepatocellular dysfunction (liver cannot synthesise factors regardless of vitamin K availability)
- CRP: Elevated in acute inflammation/infection (cholecystitis, cholangitis)
- ESR: Less specific, may be elevated [7]
- Why: Obstructive jaundice predisposes to hepatorenal syndrome and renal impairment (cholestasis → endotoxin-mediated renal vasoconstriction). Also essential as baseline before any contrast-enhanced imaging or ERCP [7]
- Why: To rule out concurrent acute pancreatitis [1]. A stone in Hartmann's pouch can occasionally also cause pancreatitis if there is distal migration or ampullary impaction. Amylase > 3× upper limit of normal suggests pancreatitis.
- CEA and CA 19-9: May be checked to evaluate for concurrent malignancy (gallbladder carcinoma or cholangiocarcinoma), but are NOT diagnostically useful since they lack sensitivity and specificity [15]. Their role is primarily in serial monitoring after resection for recurrence detection, not in primary diagnosis.
Summary of expected blood findings in Mirizzi syndrome: Leukocytosis, ↑ ALP, ↑ GGT, ↑ conjugated bilirubin, ± prolonged PT, ± elevated amylase (if concurrent pancreatitis), ± positive blood cultures (if cholangitis).
2. USG Abdomen (First-Line Imaging)
Why USG first? It is readily available, non-invasive, does not involve radiation or contrast, and is the standard first-line investigation for any patient with RUQ pain or obstructive jaundice [1][2][4].
| USG Finding | Interpretation / Pathophysiological Basis |
|---|---|
| Gallstones present | Confirms underlying cholelithiasis — the prerequisite for Mirizzi syndrome |
| Contracted gallbladder | Chronic cholecystitis → fibrosis → shrunken GB (though in acute presentations, GB may be distended) [1][2] |
| Stone impacted in the gallbladder neck | The causative stone — seen as a hyperechoic focus with posterior acoustic shadowing at the GB neck / Hartmann's pouch [1] |
| Dilatation of biliary system above the level of gallbladder neck [1] | CHD obstruction → back-pressure → intrahepatic duct dilatation. Intrahepatic ducts (normally not visible on USG at < 2–3 mm) become visible when dilated [15] |
| Abrupt change to a normal width of CBD below the level of stones [1] | This is the signature finding: the obstruction is at the level of the GB neck/cystic duct — above this point, the biliary tree is dilated; below this point, the CBD is normal calibre ( < 8 mm). This distinguishes Mirizzi from choledocholithiasis (where CBD itself is dilated) [1] |
- Operator-dependent: requires experienced sonographer [6]
- Limited by body habitus: obesity and bowel gas reduce image quality
- Cannot reliably demonstrate the cholecystobiliary fistula — this usually requires ERCP or MRCP
- Cannot exclude malignancy — a contracted, inflamed GB with pericholecystic changes can look similar to GB carcinoma on USG
- Distal CBD poorly visualized: overlying duodenal gas obscures this region [4][5]
USG Sensitivity for Mirizzi
USG has a sensitivity of only ~29–50% for diagnosing Mirizzi syndrome. It is excellent for detecting gallstones and biliary dilatation, but it cannot reliably identify the specific compression of CHD by the GB neck stone, nor can it demonstrate a fistula. This is why USG raises suspicion but MRCP/ERCP are needed for confirmation [1].
3. CT Abdomen with Contrast
| CT Finding | Interpretation |
|---|---|
| Enlarged porta hepatis lymph nodes [1] | Suggests malignancy (gallbladder carcinoma, cholangiocarcinoma, lymphoma) rather than simple Mirizzi syndrome |
| Hepatic infiltration or metastasis [1] | Direct liver invasion (segments IV/V adjacent to GB fossa) suggests GB carcinoma |
| Gallstone at GB neck with pericholecystic inflammation | Supportive of Mirizzi diagnosis — shows the inflammatory mass around the GB neck |
| Dilated intrahepatic ducts | Confirms proximal biliary obstruction |
| Normal CBD below GB neck | Supports Mirizzi over choledocholithiasis |
| No enhancing mass lesion | Argues against malignancy (though cannot 100% exclude it) |
CT is not very sensitive for biliary stones (only ~75% of gallstones are visible on CT [4]) and cannot reliably demonstrate a cholecystobiliary fistula. Its main value is excluding malignancy and evaluating the extent of inflammation.
4. MRCP (Magnetic Resonance Cholangiopancreatography)
MRCP = "MR" (magnetic resonance) + "CP" (cholangiopancreatography) — non-invasive imaging of the biliary tree and pancreatic duct using heavily T2-weighted sequences where fluid (bile) appears bright white [4].
Why MRCP? It has high sensitivity for Mirizzi syndrome [1] and plays a critical role in:
- Delineating biliary anatomy preoperatively
- Differentiating inflammatory from neoplastic pathology
- Avoiding the complications of ERCP in diagnostic-only scenarios
| MRCP Finding | Interpretation |
|---|---|
| Stone at GB neck / cystic duct (low signal filling defect) | Confirms the impacted stone causing extrinsic compression |
| Compressed or narrowed CHD at the level of the stone | Demonstrates the obstruction mechanism — CHD is narrowed from outside, not from within |
| Dilated intrahepatic ducts proximal to compression | Confirms obstruction |
| Normal CBD calibre distal to compression | Distinguishes from choledocholithiasis |
| T2-weighted images can differentiate between a neoplastic and inflammatory mass [1] | Critical for excluding GB carcinoma: inflammatory tissue has a different T2 signal pattern from neoplastic tissue. An inflammatory mass shows T2 hyperintensity (oedema = high water content = bright on T2), whereas a neoplastic mass may show heterogeneous or lower T2 signal depending on cellularity. This differentiation may not be possible on abdominal USG or CT scan [1] |
| Extent of pericholecystic inflammation [1] | Helps surgical planning — how densely inflamed is Calot's triangle? |
| Presence of cholecystobiliary fistula | May be visible as a communication between GB and CHD, though ERCP is more sensitive for this |
MRCP vs ERCP: When to Use Which?
MRCP is non-invasive, has no radiation, requires no contrast injection into the biliary tree, and carries no risk of post-procedure pancreatitis. It is the preferred diagnostic modality when you suspect Mirizzi but need better anatomical delineation than USG provides. However, MRCP is NOT therapeutic — it cannot decompress the biliary tree or remove stones [4]. If therapeutic intervention is needed, you proceed to ERCP.
- Non-contrast, non-invasive [4] — no iodinated contrast, no radiation
- Superior to USG in detecting stones in the cystic duct [8]
- Excellent for visualising the entire biliary tree in one image
- Can identify concurrent choledocholithiasis (stones within CBD)
- Differentiates inflammatory vs neoplastic mass — the key advantage over USG and CT [1]
5. ERCP (Endoscopic Retrograde Cholangiopancreatography)
ERCP = "E" (endoscopic) + "R" (retrograde) + "C" (cholangio-) + "P" (pancreatography) — an endoscopic procedure where a side-viewing duodenoscope is used to cannulate the ampulla of Vater and inject contrast retrogradely into the biliary and pancreatic ducts under fluoroscopy.
Why ERCP? Both diagnostic and therapeutic [1][2] — this is the gold standard for:
| ERCP Finding | Interpretation |
|---|---|
| Stone in the neck of gallbladder or cystic duct [1] | Identifies the causative impacted stone |
| Eccentric or excavating defect on lateral wall of CBD at the level of cystic duct or gallbladder neck [1] | This is the pathognomonic ERCP finding: the stone is compressing or eroding the CBD from the side (lateral/anterolateral), creating a crescentic or excavating defect — NOT a central filling defect as you'd see with an intraluminal CBD stone |
| Cholecystobiliary fistula demonstrated by passage of contrast material from proximal dilated biliary channels into the gallbladder [1] | If contrast injected into the CBD flows into the gallbladder (when the cystic duct should be obstructed by the stone), there must be an abnormal fistulous communication. This confirms Csendes Type II or above |
| Dilated intrahepatic ducts proximal to the compression | Confirms obstruction at the hilar/CHD level |
| Intervention | Purpose |
|---|---|
| Sphincterotomy [1] | Cutting the sphincter of Oddi to allow passage of stones and instruments; facilitates stent placement |
| Biliary stenting with endoprosthesis placement [1] | Temporary decompression of the biliary tree — reduces bilirubin, resolves cholangitis, and optimises the patient for definitive surgery. The stent bridges the obstruction, allowing bile to drain into the duodenum. |
| Stone extraction [2] | If CBD stones are found (concomitant choledocholithiasis), they can be extracted using wire baskets, extraction balloons, or mechanical lithotripsy [5] |
ERCP is invasive and carries significant risks:
- Post-ERCP pancreatitis (most common, ~3–5%) — guidewire or contrast traumatises the pancreatic duct orifice
- Perforation (duodenal or bile duct)
- Haemorrhage (from sphincterotomy site)
- Cholangitis (introducing bacteria with instrumentation)
- Bacteraemia — hence antibiotic prophylaxis is required [4]
ERCP: When to Use It
ERCP should be reserved for when therapeutic intervention is needed (biliary decompression, stone removal) or when MRCP is inconclusive and you need to definitively assess for a cholecystobiliary fistula. Do NOT use ERCP purely for diagnosis if MRCP can provide the answer — the risk profile of ERCP is too high for a purely diagnostic study [2][4].
6. Additional / Adjunct Investigations
- Performed during cholecystectomy by injecting contrast via the cystic duct under fluoroscopy
- Many cases of Mirizzi syndrome are first diagnosed intraoperatively via IOC when the surgeon encounters unexpected biliary anatomy or a fistula
- Exploration of CBD (ECBD) should be performed in all patients with cholecystobiliary fistula to rule out concomitant choledocholithiasis unless already done endoscopically [1]
- Preferred to ERCP when obstruction is at or above the level of the hepatic confluence [4]
- In Mirizzi syndrome (hilar-level obstruction), PTC can access the dilated intrahepatic system from above and provide drainage
- Complications: bacteraemia, haemobilia [4]
- Rarely needed as ERCP can usually manage Mirizzi syndrome adequately
- Can provide detailed images of the GB neck, cystic duct, and adjacent structures
- Useful for FNAC or trucut biopsy if there is suspicion of malignancy [15]
- Less commonly used in Mirizzi workup specifically but valuable when imaging is equivocal for malignancy
| Investigation | Role in Mirizzi Syndrome | Key Findings | Limitations |
|---|---|---|---|
| CBC D/C | Assess infection | Leukocytosis, neutrophilia | Non-specific |
| LFT | Confirm obstruction | ↑ ALP, ↑ bilirubin (cholestatic pattern) [1] | Does not localise |
| Clotting | Assess coagulopathy | Prolonged PT/INR | |
| USG (1st line) | Initial assessment | Stone at GB neck, dilated IHD, normal CBD below [1][2] | Sensitivity only 29–50%; cannot show fistula; operator-dependent |
| CT + contrast | Exclude malignancy | Porta hepatis LN, liver invasion [1][2] | Poor for gallstone detection; cannot show fistula |
| MRCP | Confirm diagnosis; differentiate inflammatory vs neoplastic | T2 differentiates neoplastic from inflammatory mass [1]; biliary anatomy | Not therapeutic |
| ERCP | Confirm fistula + therapeutic | Eccentric CBD defect, contrast into GB via fistula [1]; stenting, sphincterotomy [1][2] | Invasive; risk of pancreatitis, perforation, bleeding |
| IOC | Intraoperative diagnosis | Unexpected biliary anatomy / fistula | Only available during surgery |
| Tumour markers | Exclude malignancy | CEA, CA 19-9 | Not diagnostically useful — lack sensitivity and specificity [15] |
High Yield Summary
Diagnostic criteria: No formal criteria exist. Diagnosis is based on clinical suspicion + imaging confirmation of (1) stone at GB neck, (2) CHD obstruction at that level, (3) exclusion of malignancy, (4) assessment of cholecystobiliary fistula.
First-line investigation: USG abdomen — look for the signature triad: stone at GB neck + dilated IHD above + normal CBD below.
CT abdomen + contrast: Essential to rule out malignancy (porta hepatis LN, liver invasion).
MRCP: High sensitivity, non-invasive, differentiates inflammatory from neoplastic mass on T2-weighted images — something USG and CT cannot reliably do.
ERCP: Both diagnostic and therapeutic — confirms cholecystobiliary fistula (contrast passes from CBD into GB), determines Csendes type, and enables sphincterotomy + biliary stenting for temporary decompression.
Blood tests: Cholestatic LFT pattern (↑ ALP, ↑ conjugated bilirubin, ↑ GGT), leukocytosis, prolonged PT (correct with vitamin K before intervention).
Most cases diagnosed intraoperatively — preoperative diagnosis rate only 8–27%.
Active Recall - Mirizzi Syndrome Diagnosis and Investigations
[1] Senior notes: felixlai.md (Mirizzi syndrome diagnosis, pp. 573–574; treatment and ECBD, p. 575) [2] Senior notes: maxim.md (Mirizzi syndrome investigations and management, pp. 131–132) [3] Lecture slides: Malignant biliary obstruction.pdf (Manifestations of pathophysiological disturbance of MBO: bleeding tendency, infection, poor wound healing) [4] Senior notes: maxim.md (HBP investigations: USG, MRCP, ERCP, PTC, pp. 250–251) [5] Senior notes: maxim.md (Choledocholithiasis investigations and stone removal, p. 136) [6] Senior notes: maxim.md (Biliary colic investigations: USG, AXR, p. 130) [7] Senior notes: felixlai.md (Acute cholangitis diagnostic criteria — Tokyo Guidelines, p. 521) [8] Senior notes: felixlai.md (Acute cholecystitis diagnostic criteria — Tokyo Guidelines 2013, physical examination, pp. 555–557) [15] Senior notes: felixlai.md (MBO biochemical tests and radiological tests, pp. 502–503) [16] Senior notes: maxim.md (Acute cholangitis urgent investigations — blood culture, p. 135)
Management of Mirizzi Syndrome
Before diving into type-specific surgery, let's establish the fundamental management philosophy. There are three layers to managing Mirizzi syndrome:
- Acute stabilisation — resuscitate, treat sepsis, decompress the biliary tree
- Preoperative optimisation — correct coagulopathy, reduce bilirubin, ensure fitness for surgery
- Definitive surgery — remove the gallbladder and impacted stone, and address any cholecystobiliary fistula according to Csendes type
Surgery is the mainstay of therapy permitting removal of causal factors including the inflamed gallbladder and the impacted stones [1].
Why Surgery Is Essential
Unlike simple choledocholithiasis (where ERCP + sphincterotomy can remove CBD stones and you may defer cholecystectomy), Mirizzi syndrome requires cholecystectomy because the causative stone is impacted in the gallbladder neck — it cannot be extracted endoscopically via the CBD. The gallbladder itself is the source of the problem and must be removed. ERCP plays only a bridging role (biliary decompression/stenting) to optimise the patient before definitive surgery [1][2].
Phase 1: Acute Stabilisation and Resuscitation
If the patient presents with acute cholangitis (Charcot's triad or Reynolds' pentad) or acute cholecystitis, immediate management follows the RAD principle [16]:
- NPO (nil per os) — bowel rest
- IV fluid resuscitation — correct dehydration and maintain urine output
- Monitor vitals and I/O — look for signs of shock (hypotension, tachycardia, oliguria, altered mental status, cold clammy skin) [7]
- Continuous monitoring of vitals to look for signs of failure of conservative treatment: ↑ Temperature / Pulse; ↓ BP / Consciousness level / Urine output; Increased abdominal tenderness and guarding [7]
Why these antibiotics? The common biliary pathogens are enteric Gram-negatives (E. coli, Klebsiella) and anaerobes. Augmentin covers these adequately for mild cases. Tazocin has broader Gram-negative and Pseudomonas coverage for severe/nosocomial infections. Metronidazole specifically covers anaerobes.
- 15% of patients will NOT respond to antibiotics alone and require emergency biliary decompression [7]
- Indications for urgent drainage:
Hierarchy of drainage (QMH practice: ERCP → PTBD → ECBD) [7]:
| Modality | Details | When to Use |
|---|---|---|
| ERCP (1st line) [7][16][17] | Sphincterotomy + biliary stenting with endoprosthesis placement to allow temporary decompression of biliary tree [1]. Aspirate bile/pus to decompress. Plastic stent placed across the obstruction. Mortality < 5% [16]. | First-line for biliary decompression. ERCP is ALWAYS 1st line regardless of the level of obstruction [19] except when contraindicated. |
| PTBD (2nd line) [7][16] | Percutaneous transhepatic biliary drainage — catheter inserted through the liver into dilated intrahepatic ducts. Can be external or external-internal drainage. | When ERCP is unsuccessful or contraindicated (e.g. altered GI anatomy — Billroth II, Roux-en-Y) [16][17] |
| ECBD (3rd line) [7][17] | Surgical exploration of common bile duct — open approach with T-tube placement. High mortality (~30%) [16]. | Failure of endoscopic drainage OR deterioration despite endoscopic drainage [17]. Open approach for emergency cases [17]. |
ERCP for Decompression, NOT Definitive Treatment
In Mirizzi syndrome, ERCP is used for temporary biliary decompression (stenting) and assessment of fistula — it is NOT the definitive treatment. The definitive treatment is surgery. The stent bridges the obstruction, allows bilirubin to drop, resolves cholangitis, and optimises the patient for safe elective surgery [1][2].
Once the acute episode is controlled, the patient must be optimised before definitive surgery:
| Issue | Correction | Rationale |
|---|---|---|
| Coagulopathy | Vitamin K 10 mg IV/IM × 24–48 hours preoperatively; FFP if urgent | Obstructive jaundice → Vit K malabsorption → ↓ factors II, VII, IX, X [3] |
| Hyperbilirubinaemia | Allow ERCP stent to decompress biliary tree for 2–4 weeks; bilirubin should trend downwards | Operating in deep jaundice → poor wound healing, infection risk, hepatorenal syndrome [3] |
| Nutrition | Optimise protein/caloric intake; consider pre-albumin monitoring | Chronic biliary obstruction → impaired protein synthesis → poor anastomotic healing [3] |
| Sepsis resolution | Complete antibiotic course; ensure afebrile with normalising WCC | Operating during active sepsis dramatically increases morbidity and mortality |
| Renal function | Adequate hydration; monitor UO; avoid nephrotoxic agents | Obstructive jaundice predisposes to renal impairment |
| Malignancy assessment | CT ± MRCP to exclude concurrent gallbladder carcinoma | 5–28% coexistence rate — changes surgical plan entirely [1][2] |
Definitive treatment should be deferred until cholangitis has been treated and the proper diagnosis is established [7]
Phase 3: Definitive Surgical Management — By Csendes Type
The treatment approach is based on the presence and type of cholecystobiliary fistula [1][2].
This is the core exam-testable content. The logic is straightforward:
- No fistula (Type I): Remove the gallbladder — the bile duct wall is intact, no repair needed
- Small fistula (Type II): Remove the gallbladder + close the small hole in the bile duct
- Moderate fistula (Type III): The hole is too big for simple closure — consider bilioenteric anastomosis
- Complete destruction (Type IV): The entire CBD wall is gone — you MUST bypass with bilioenteric anastomosis
- Cholecystoenteric fistula (Type V): Address the bowel problem (gallstone ileus if present) AND the biliary fistula
Pathology: Extrinsic compression of CHD by stone — bile duct wall intact.
Surgery: Partial or total cholecystectomy (laparoscopic or open) [1]
- ECBD (exploration of CBD) is typically NOT required [1] — because there is no fistula and the bile duct wall is intact, there is nothing to repair in the CBD
- Laparoscopic approach is feasible in select cases but carries high risk of conversion to open due to dense adhesions
- If the critical view of safety cannot be achieved (anatomy distorted by inflammation), consider:
- Intraoperative cholangiogram (IOC) to delineate anatomy
- Subtotal (partial) cholecystectomy — leave the posterior wall of the GB attached to the liver bed and remove the rest, rather than risking bile duct injury by forcing a complete dissection
Why laparoscopic is difficult: Laparoscopic management of Mirizzi syndrome can be difficult due to dense adhesions and edematous inflammatory tissue cause distortion of normal anatomy and increase the risk of biliary injury [1]. Calot's triangle is obliterated by fibrosis. The cystic duct, cystic artery, and CHD are fused together. The Critical View of Safety — normally requiring clear identification of only two structures entering the gallbladder (cystic duct and cystic artery) with clearance of the hepatocystic triangle and cystic plate [20][21] — is often impossible to obtain.
Critical View of Safety
The Critical View of Safety (CVS) is the gold standard for preventing bile duct injury during cholecystectomy [21]. It requires: (1) hepatocystic triangle cleared of fat and fibrous tissue, (2) lower 1/3 of cystic plate visible, (3) only two structures seen entering the gallbladder: cystic duct and cystic artery [21]. In Mirizzi syndrome, achieving CVS is frequently impossible due to dense inflammation. Difficulty with obtaining the critical view should lead the surgeon to consider performing IOC or converting to open [20]. Never clip or divide a structure you cannot positively identify.
Pathology: Small cholecystobiliary fistula — most of the CBD wall is intact.
Surgery: Cholecystectomy plus closure of fistula [1] using one of:
- Suture repair with absorbable material — primary closure of the small defect in the bile duct wall
- T-tube placement — a T-shaped tube placed in the CBD to stent the repair, with the long limb exiting through the abdominal wall. Allows postoperative cholangiogram to check for leaks and residual stones. The T-tube is removed after 2–4 weeks once a fibrous tract has formed.
- Choledochoplasty with remnant gallbladder — using a pedicled flap of the gallbladder wall (the remnant after subtotal cholecystectomy) to patch the defect in the CBD. This is elegant because it uses autologous tissue with a blood supply.
Why these options? The defect is small ( < 1/3 circumference), so the remaining CBD wall has enough structural integrity to support a primary repair. There is no need for a bypass because the duct can be reconstructed.
Pathology: Moderate-sized fistula — significant CBD wall destruction but not complete.
Surgery: Cholecystectomy OR bilioenteric anastomosis [1]
- Bilioenteric anastomosis includes choledochoduodenostomy, choledochojejunostomy, or cholecystoduodenostomy [1]
- Suture of the fistula is NOT required [1] — because the defect is too large for primary closure; attempting to close it would cause stricture due to tension on the suture line
Why bilioenteric anastomosis? When > 1/3 of the CBD circumference is destroyed, primary repair would narrow the duct lumen (tension on the remaining edges), leading to postoperative biliary stricture. Instead, you bypass the damaged segment by connecting the proximal healthy bile duct directly to a loop of bowel, allowing bile to drain into the intestine via a new route.
The choice between different anastomosis types:
- Choledochoduodenostomy: simpler; CBD → duodenum. Risk of "sump syndrome" (food debris/bacteria accumulating in the CBD stump distal to the anastomosis)
- Choledochojejunostomy (Roux-en-Y): CBD → jejunal limb. More complex but lower risk of reflux cholangitis because the Roux limb keeps food/bacteria away from the biliary anastomosis
- Cholecystoduodenostomy is rarely used
Pathology: Near-complete or complete destruction of the CBD wall.
Surgery: Bilioenteric anastomosis — typically choledochojejunostomy since the entire wall of CBD has been destroyed [1]
Why choledochojejunostomy specifically? With complete CBD wall destruction, there is no CBD left to repair. You must create a Roux-en-Y hepaticojejunostomy/choledochojejunostomy — bringing a loop of jejunum up to the proximal healthy bile duct (common hepatic duct or hepatic duct stumps) and creating an end-to-side or side-to-side anastomosis. The Roux-en-Y configuration is preferred over choledochoduodenostomy in this scenario because it provides a longer defunctioned limb, reducing the risk of ascending cholangitis from intestinal content reflux.
Pathology: Mirizzi syndrome (any Csendes type) coexisting with a cholecystoenteric fistula (communication between GB and bowel) [2]. If a large stone has passed into the bowel and caused obstruction → gallstone ileus (Type 5B).
Surgery — Two separate problems to address:
A. If gallstone ileus present (Type 5B) — address the bowel obstruction first:
- Enterolithotomy to relieve SBO [2]:
- Exploratory laparotomy
- Proximal enterotomy (NOT over the stone because of ulceration) [2] — the bowel wall at the site of stone impaction is inflamed and ulcerated; cutting there risks breakdown of the enterotomy closure
- Milk the stone proximally for extraction [2]
- Inspect the entire bowel for additional stones (second stone found in ~3–16% of cases)
- Then: Same-session or elective cholecystectomy + fistula repair [2]
B. Biliary fistula — manage per the corresponding Csendes type (I–IV) as described above
| Csendes Type | Fistula | Surgery on Gallbladder | Surgery on Bile Duct | ECBD Required? |
|---|---|---|---|---|
| I | None | Partial or total cholecystectomy (laparoscopic or open) [1] | None — duct wall intact | NOT required [1] |
| II | < 1/3 CBD | Cholecystectomy (usually subtotal) | Suture repair / T-tube / Choledochoplasty with GB remnant [1] | Yes (to rule out CBD stones) [1] |
| III | 1/3–2/3 CBD | Cholecystectomy | Bilioenteric anastomosis [1]; suture NOT required [1] | Yes [1] |
| IV | > 2/3 CBD | Cholecystectomy | Bilioenteric anastomosis (typically choledochojejunostomy) [1] | Yes [1] |
| V | Any + cholecystoenteric | Cholecystectomy + fistula repair | Per type above | Yes [1] |
ECBD should be performed in all patients with cholecystobiliary fistula to rule out concomitant choledocholithiasis (CBD stones) unless it has been performed endoscopically [1]
| Factor | Laparoscopic | Open |
|---|---|---|
| Feasibility in Mirizzi | Feasible mainly for Type I (simple compression, no fistula) [1][2] | Required for Types II–V due to fistula complexity [2] |
| Advantages | Less pain, shorter stay, faster recovery, better cosmesis [20] | Better exposure for complex biliary reconstruction |
| Disadvantages | Higher risk of biliary injury due to distorted anatomy and dense adhesions [1][20] | Larger incision, longer recovery |
| Conversion | Should never be viewed as failure — it is a safety measure [20] | — |
With fistula (Types II–V): open surgery [2]:
- GB: Subtotal cholecystectomy (severe inflammation impedes safe dissection of Calot's triangle) [2]
- CBD: Closure of fistula / choledochoplasty / bilioenteric anastomosis (choledochojejunostomy) depending on size of defect [2]
Special Situations
If intraoperative frozen section reveals gallbladder carcinoma:
- Abort the standard Mirizzi surgery
- Proceed to oncological resection: open cholecystectomy with intraoperative frozen section → if beyond stage T1a, perform extended cholecystectomy with en-bloc resection of liver segments IVb/V, extrahepatic bile duct resection (if cystic duct margin involved), and regional lymphadenectomy [9]
- Percutaneous cholecystostomy: drainage of the gallbladder for patients who are haemodynamically unstable, high surgical risk, or have severe comorbidities [22][18]
- Indications: high surgical risk, haemodynamically unstable, difficult cholecystectomy [18]
- Can be percutaneous (USG/CT-guided) or endoscopic (ERCP/EUS-guided)
- Allows decompression and infection control as a bridge to interval surgery or as definitive palliation in the very frail
- Long-term ERCP stenting can be used as definitive palliation in patients truly unfit for any surgery — stent exchanges every 3–6 months to prevent occlusion
In very select cases (elderly, high ASA grade, Type I only), some centres have reported managing Mirizzi Type I non-operatively with ERCP stone extraction ± electrohydraulic lithotripsy, but this is not standard of care and recurrence is high.
| Scenario | Contraindication / Caution | Alternative |
|---|---|---|
| Laparoscopic approach in Types II–V | Relative contraindication — fistula requires open reconstruction; dense adhesions → high risk of bile duct injury [1][2] | Open surgery with subtotal cholecystectomy [2] |
| ERCP | Contraindicated in altered GI anatomy (Billroth II, Roux-en-Y) [17][19]; unstable cardiopulmonary disease; known/suspected perforation; structural upper GI abnormalities [23] | PTBD or surgical drainage |
| Operating during active sepsis | Relative contraindication — dramatically increases morbidity. Stabilise first with RAD [7][16] | Biliary decompression → interval surgery |
| Operating in deep jaundice | Relative contraindication — poor wound healing, bleeding tendency, hepatorenal risk [3] | Preoperative biliary drainage via ERCP stent × 2–4 weeks to lower bilirubin |
| Concurrent malignancy | Standard Mirizzi surgery is contraindicated — must perform oncological resection or palliation depending on staging [9] | Extended cholecystectomy or palliative stenting |
| Refractory coagulopathy | Relative contraindication for laparoscopic surgery | Open approach; correct coagulopathy with FFP/Vit K [20] |
-
T-tube management (if placed):
- Check tube cholangiogram at 7–10 days postoperatively to confirm no leak and no residual stones
- If cholangiogram is normal → clamp T-tube → if patient tolerates (no pain, no fever) → remove after fibrous tract has matured (~2–4 weeks)
- T-tubes have been shown to increase complications (infection, bile leak, tube dislodgement) compared to primary closure [5]
-
Follow-up imaging: USG at 3–6 months to assess for biliary stricture (a late complication of fistula repair)
-
Histopathology: Send all gallbladder specimens for histological examination — given the 5–28% risk of concurrent gallbladder carcinoma, intraoperative frozen section and final histology are essential
-
Long-term: Monitor for biliary stricture, recurrent cholangitis, or missed malignancy
High Yield Summary
Management framework: RAD (Resuscitate → Antibiotics → Drainage) for acute presentation → Preoperative optimisation → Definitive surgery based on Csendes type.
ERCP role: Temporary biliary decompression (sphincterotomy + stenting) [1] — NOT definitive treatment. Hierarchy: ERCP → PTBD → ECBD [7].
Surgical management by type:
- Type I (no fistula): Cholecystectomy (lap or open); ECBD NOT required [1]
- Type II ( < 1/3): Cholecystectomy + fistula closure (suture/T-tube/choledochoplasty) [1]
- Type III (1/3–2/3): Cholecystectomy OR bilioenteric anastomosis; suture NOT required [1]
- Type IV ( > 2/3): Bilioenteric anastomosis (choledochojejunostomy) [1]
- Type V: Address gallstone ileus (enterolithotomy) if present + manage biliary fistula per type [2]
Key principles:
- ECBD in all fistula types to rule out CBD stones unless done endoscopically [1]
- Types II–V: open surgery with subtotal cholecystectomy (Calot's triangle too inflamed for safe dissection) [2]
- Critical View of Safety often unachievable → low threshold to convert to open [20][21]
- Always send gallbladder for histology — rule out concurrent CA gallbladder
Active Recall - Mirizzi Syndrome Management
References
[1] Senior notes: felixlai.md (Mirizzi syndrome treatment, pp. 574–575) [2] Senior notes: maxim.md (Mirizzi syndrome management and gallstone ileus, pp. 131–132) [3] Lecture slides: Malignant biliary obstruction.pdf (Manifestations of pathophysiological disturbance of MBO) [5] Senior notes: maxim.md (Choledocholithiasis management — T-tube complications, p. 136) [7] Senior notes: felixlai.md (Acute cholangitis treatment — biliary decompression hierarchy, QMH practice, p. 522) [9] Senior notes: maxim.md (Gallbladder carcinoma treatment — extended cholecystectomy, p. 139) [16] Senior notes: maxim.md (Acute cholangitis acute management — RAD, p. 135) [17] Lecture slides: GC 200. RUQ pain, jaundice and fever Cholecytitis and cholangitis Imaging of GI system.pdf (Acute cholangitis management — ERCP, antibiotics, ECBD, pp. 13–15) [18] Lecture slides: GC 200. RUQ pain, jaundice and fever Cholecytitis and cholangitis Imaging of GI system.pdf (Cholecystostomy indications, p. 12) [19] Senior notes: felixlai.md (ERCP is always 1st line for biliary drainage, p. 504) [20] Senior notes: felixlai.md (Cholecystectomy — CVS, conversion to open, subtotal cholecystectomy, pp. 513–514) [21] Senior notes: maxim.md (Critical View of Safety, p. 133) [23] Senior notes: felixlai.md (ERCP contraindications, p. 87)
Complications of Mirizzi Syndrome
Complications of Mirizzi syndrome can be organised into three categories:
- Complications of the disease itself (from the pathological process of stone impaction, CHD compression, and chronic inflammation)
- Complications of associated conditions (from concurrent cholecystitis, cholangitis, pancreatitis)
- Complications of treatment (from ERCP and from surgery)
Understanding why each complication occurs — tracing it back to the underlying pathophysiology — is far more useful than memorising a list.
A. Complications of the Disease Process
These arise directly from the stone impaction, chronic inflammation, and biliary obstruction that define Mirizzi syndrome.
- Mechanism: The impacted stone exerts chronic pressure on the adjacent bile duct wall. Combined with inflammation-mediated ischaemia and pressure necrosis, the stone erodes through the gallbladder/cystic duct wall and the CHD/CBD wall, creating an abnormal communication [1][2]
- Why it matters: This is not just a complication — it defines the progression of Mirizzi syndrome from Type I (compression only) to Types II–IV. The fistula fundamentally changes the surgical approach: primary repair vs. bilioenteric anastomosis. The larger the fistula, the more complex the surgery.
- Consequence: Once a fistula exists, stones can migrate from the gallbladder into the CBD (causing secondary choledocholithiasis), and the structural integrity of the bile duct is compromised
- Mechanism: Recurrent inflammation and biliary stasis may predispose to both conditions [1]. The chronic inflammatory milieu — repeated cycles of mucosal injury, regeneration, and fibrosis — drives a dysplasia-carcinoma sequence (analogous to Barrett's → oesophageal adenocarcinoma, or UC → colorectal cancer). Chronic inflammation generates reactive oxygen species, DNA damage, and promotes proliferative signalling.
- CA gallbladder is a recognized complication/association of Mirizzi syndrome [2]. Reported coexistence rate: 5–28% across various surgical series.
- Why it matters: This is the reason you must always perform CT abdomen + contrast preoperatively (to look for enlarged porta hepatis LNs or hepatic infiltration of metastasis [1]) and why MRCP is important (T2-weighted images can differentiate between a neoplastic and inflammatory mass [1]). Intraoperative frozen section of the gallbladder specimen should always be sent.
CA Gallbladder in Mirizzi
Never assume an inflammatory mass at the GB neck is "just" Mirizzi syndrome. With a 5–28% coexistence rate of gallbladder carcinoma, you must actively exclude malignancy in every single case. If frozen section returns positive for malignancy, the surgical plan changes completely — you need an oncological resection (extended cholecystectomy with hepatic segments IVb/V resection + lymphadenectomy) rather than simple fistula repair [2].
- Mechanism: Once a cholecystobiliary fistula forms (Types II–IV), gallstones can migrate from the gallbladder through the fistula directly into the CBD. Additionally, bile stasis proximal to the obstruction promotes de novo stone formation within the bile ducts.
- Why it matters: This is why ECBD should be performed in all patients with cholecystobiliary fistula to rule out concomitant choledocholithiasis (CBD stones) unless it has been performed endoscopically [1]. Missed CBD stones after Mirizzi surgery will cause recurrent cholangitis and obstructive jaundice.
- Mechanism: The same chronic inflammatory and erosive process that creates a cholecystobiliary fistula can also erode through the gallbladder wall into adjacent bowel — most commonly the duodenum (cholecystoduodenal fistula, MC [2])
- Once the fistula exists, a large gallstone can pass from the gallbladder through the fistula into the bowel lumen. If the stone is large enough ( > 2–2.5 cm), it impacts at the narrowest part of the small bowel — the terminal ileum, 2 feet proximal to the ileocaecal valve [2] — causing mechanical small bowel obstruction: gallstone ileus
- Bouveret's syndrome: stone stuck at the duodenum/stomach, causing gastric outlet obstruction [2]
- Imaging findings: Rigler's triad on AXR: pneumobilia + SBO + ectopic gallstone [2]
- Pneumobilia (air in the biliary tree) occurs because the cholecystoenteric fistula allows bowel gas to reflux into the biliary system
- Management: Enterolithotomy to relieve SBO — proximal enterotomy (NOT over the stone because of ulceration) → milk the stone proximally for extraction → same-session or elective cholecystectomy + fistula repair [2]
Gallstone Ileus — A Surgical Emergency
Gallstone ileus (Csendes Type 5B) is one of the few complications of Mirizzi syndrome that presents as an acute surgical emergency with complete bowel obstruction. Immediate priorities are bowel decompression and relief of the obstruction by enterolithotomy. Definitive biliary surgery can be addressed at the same sitting or electively [2].
- Mechanism: CHD obstruction → bile stasis → bacterial colonisation of stagnant bile → ascending infection. Common organisms: E. coli, Klebsiella, anaerobes. The liver's Kupffer cells normally clear gut-derived endotoxins from the portal blood, but in biliary obstruction, this function is impaired → endotoxaemia [3].
- Presentation: Charcot's triad (fever + jaundice + RUQ pain) in ~50–70% of cholangitis cases. If untreated → suppurative cholangitis with Reynolds' pentad (Charcot's + hypotension + altered mental status) in < 10% — a life-threatening emergency [7]
- Why it matters: Cholangitis is the most common acute complication requiring emergency intervention (RAD: Resuscitate → Antibiotics → Drainage) [16]
- Up to 1/3 of patients with Mirizzi syndrome have acute cholecystitis on presentation [1]
- Mechanism: The same stone impaction at Hartmann's pouch that compresses the CHD also obstructs gallbladder outflow → bile stasis within the GB → chemical inflammation (first 48 hours) → secondary bacterial infection [6]
- Can progress to: gallbladder empyema (pus-filled GB), gangrenous cholecystitis (wall necrosis from ischaemia), perforation (necrotic wall ruptures → biliary peritonitis) [6]
- In rare cases, acute pancreatitis can complicate Mirizzi syndrome [1]
- Mechanism: If the stone at Hartmann's pouch is large enough or positioned low enough, or if smaller stones migrate distally, they can obstruct the ampulla of Vater or pancreatic duct → impaired pancreatic enzyme drainage → premature intra-acinar enzyme activation → autodigestion → acute pancreatitis
- This is the same mechanism as gallstone pancreatitis from choledocholithiasis
- Mechanism: Long-standing, unrelieved biliary obstruction → chronic cholestasis → periductal fibrosis → progressive hepatic fibrosis → biliary cirrhosis. This is a rare long-term complication seen in delayed or missed diagnosis.
These are the consequences of obstructive jaundice itself, applicable to any cause of obstruction but directly relevant to Mirizzi syndrome. They are also the reasons why preoperative optimisation is critical [3].
| Complication | Mechanism | Clinical Significance |
|---|---|---|
| Bleeding tendency [3] | Obstructive jaundice → no bile salts in gut → impaired absorption of fat-soluble vitamin K → ↓ hepatic synthesis of factors II, VII, IX, X → coagulopathy | Must correct with Vitamin K IV before any invasive procedure; check PT/INR |
| Infection / biliary sepsis [3] | Endotoxaemia when liver is unable to defend against gut endotoxins + impaired reticuloendothelial function + impaired cell-mediated immunity [3] | Broad-spectrum antibiotics mandatory; these patients are immunocompromised by their obstruction |
| Poor wound healing / poor anastomotic healing [3] | Impaired protein synthesis → hypoalbuminaemia → poor tissue repair + impaired collagen cross-linking | Nutritional optimisation preoperatively; higher risk of anastomotic leak/stricture |
| Renal impairment | Cholestasis → endotoxin-mediated renal vasoconstriction + systemic vasodilatation → hepatorenal physiology | Aggressive IV hydration; avoid nephrotoxins; monitor UO |
C. Complications of Treatment
ERCP is used for preoperative biliary decompression (stenting) and fistula assessment. It carries a recognised complication profile [23][17]:
| Complication | Incidence | Mechanism | Management |
|---|---|---|---|
| Post-ERCP pancreatitis [23] | ~2% (MOST frequent complication [23]) | Manipulation of the pancreatic orifice during cannulation → pancreatic duct oedema → impaired drainage → enzyme activation → pancreatitis | Supportive: NPO, IV fluids, analgesia. Prevent: pancreatic duct stent, guidewire cannulation |
| Cholangitis [23] | ~0.6% | Manipulation of an obstructed biliary system → introduction of bacteria / failure to achieve complete drainage | IV antibiotics; repeat drainage if stent is blocked |
| Bleeding [23][17] | ~2% post-sphincterotomy | Bleeding from papillotomy [17] — cutting the sphincter of Oddi severs submucosal vessels | Endoscopic haemostasis (injection, clipping). Prevent: correct coagulopathy pre-procedure |
| Perforation [23][17] | ~1% | Duodenal wall injury from scope manipulation; guidewire perforation of bile duct; sphincterotomy extending beyond the duodenal wall | If contained → conservative (NPO, antibiotics, NGT). If free → surgical repair |
| Stent occlusion/migration [23] | Late | Sludge/biofilm accumulation (plastic stents) or tumour ingrowth (metallic stents); stent displacement | Repeat ERCP for stent exchange |
Surgery for Mirizzi syndrome is inherently more complex and higher risk than routine cholecystectomy because of the dense inflammation, distorted anatomy, and potential need for bile duct reconstruction.
Immediate (intraoperative):
| Complication | Mechanism in Mirizzi Context |
|---|---|
| Bile duct injury (most feared) | Dense adhesions and edematous inflammatory tissue cause distortion of normal anatomy and increase the risk of biliary injury [1]. The CHD, cystic duct, and cystic artery are fused in a mass of fibrosis. The surgeon may inadvertently clip, divide, or cauterise the CHD or right hepatic duct thinking it is the cystic duct. This is why the critical view of safety is essential — and why it is often unachievable in Mirizzi, necessitating conversion to open [1][2]. |
| Conversion to open surgery | Not truly a "complication" but a safety measure: 5% in elective, 25% in emergency cholecystectomy [21]. In Mirizzi syndrome, conversion rates are much higher (30–60%) due to inability to safely identify structures. |
| Vascular injury (cystic artery, right hepatic artery) | The right hepatic artery may loop into the inflamed Calot's triangle as an anatomical variant. In the fibrotic, distorted field of Mirizzi surgery, it can be injured. Also risk of injury to the middle hepatic vein close to the GB fossa [21]. |
| Damage to neighbouring structures [21] | Bile leakage (biliary tree), bleeding (cystic artery), pneumoperitoneum from injury to duodenum, transverse colon, hepatic flexure [21] |
Early (postoperative, days to weeks):
| Complication | Mechanism | Management |
|---|---|---|
| Biliary leakage [21] | From cystic duct stump, fistula repair site, or duct of Luschka. Incidence ~0.5% in standard cholecystectomy but higher in Mirizzi surgery due to complex bile duct reconstruction [21]. Delayed presentation (post-op D2–10): fever, RUQ pain, deranged LFT [21] | USG/CT → HIDA scan/MRCP to confirm → ERCP stent (minor) or laparotomy + lavage + Roux-en-Y hepaticojejunostomy (major) [21] |
| Post-operative jaundice | Residual/missed CBD stones (dropped or migrated through fistula), oedema at repair/anastomosis site, inadvertent bile duct ligation | Check tube cholangiogram (if T-tube in situ); MRCP; ERCP for stone extraction |
| Post-operative cholangitis | Infected residual stone, stent occlusion, anastomotic stenosis | IV antibiotics + biliary drainage |
| Wound infection | Contaminated field (bile spillage during surgery); poor wound healing from obstructive jaundice [3] | Antibiotics; wound care |
| Intra-abdominal collection / subphrenic abscess | Inadequate lavage; bile leak; haematoma infection | Drainage + antibiotics [21] |
Late (weeks to months to years):
| Complication | Mechanism | Management |
|---|---|---|
| Bile duct stricture [21] | Scarring at the fistula repair site, suture-line fibrosis, ischaemic injury during dissection. This is the most frequent long-term complication of biliary reconstruction. Presents with recurrent jaundice, cholangitis [25] | Reconstruction ± hepaticojejunostomy [21]; endoscopic balloon dilatation + stenting for accessible strictures |
| Recurrent cholangitis | Stricture formation → bile stasis → stone formation → infection (same pathological cycle as RPC). Also possible after cholecystectomy due to biliary stasis from ERCP-induced CBD dilatation or aging-related CBD dilatation [16] | Antibiotics; ERCP for stone clearance / stricture dilatation; revision surgery if recurrent |
| Post-cholecystectomy syndrome [21] | Persistent symptoms (e.g. biliary colic, diarrhoea) after operation [21]. May be due to residual stones, sphincter of Oddi dysfunction, bile salt malabsorption, or unrecognised concurrent pathology | Investigate: MRCP, ERCP, manometry. Treat underlying cause |
| Post-cholecystectomy choledocholithiasis [21] | Bile stasis due to increased CBD calibre (loss of GB storing function) [21] — after GB removal, bile flows continuously into the CBD rather than being stored, potentially leading to CBD dilatation and stasis | ERCP stone clearance |
| Anastomotic stricture (after bilioenteric anastomosis) | Scarring at the hepaticojejunostomy/choledochojejunostomy site — the most frequent long-term complication of Roux-en-Y hepatojejunostomy is stenosis of biliary-enteric anastomosis leading to jaundice, cirrhosis or cholangitis [25] | Percutaneous or endoscopic dilatation; revision hepaticojejunostomy |
Bile Duct Injury — The Most Feared Complication
Iatrogenic bile duct injury during cholecystectomy for Mirizzi syndrome is the single most feared surgical complication. The dense inflammation makes the anatomy unrecognisable. The conversion rate to open is high. If the CHD is transected, the repair is a major Roux-en-Y hepaticojejunostomy — a life-altering operation with long-term stricture risk. This is why preoperative MRCP and ERCP are so important — they delineate the anatomy before the surgeon enters a hostile operative field, and they classify the Csendes type so the team can plan the appropriate reconstruction in advance [1][2].
| Category | Complication | Key Mechanism |
|---|---|---|
| Disease progression | Cholecystobiliary fistula (Types II–IV) | Chronic pressure necrosis → bile duct wall erosion |
| CA Gallbladder | Chronic inflammation → dysplasia-carcinoma sequence | |
| Choledocholithiasis | Stone migration via fistula into CBD | |
| Cholecystoenteric fistula ± gallstone ileus | Erosion into bowel; stone obstructs terminal ileum | |
| Acute presentations | Acute cholangitis / biliary sepsis | Bile stasis → bacterial colonisation → ascending infection |
| Acute cholecystitis (1/3 of cases) | Stone impaction → gallbladder inflammation | |
| Acute pancreatitis (rare) | Stone / inflammation obstructs ampulla | |
| Hepatic abscess | Ascending infection into intrahepatic ducts | |
| Systemic effects of obstruction | Coagulopathy | Vitamin K malabsorption |
| Immunosuppression / sepsis | Impaired Kupffer cell and cell-mediated immunity | |
| Poor healing | Impaired protein synthesis | |
| Renal impairment | Endotoxin-mediated renal vasoconstriction | |
| Treatment-related (ERCP) | Post-ERCP pancreatitis (most common) | Manipulation of pancreatic orifice |
| Bleeding, perforation, cholangitis | Sphincterotomy, scope trauma, bacterial introduction | |
| Treatment-related (Surgery) | Bile duct injury (most feared) | Distorted anatomy from dense adhesions |
| Biliary leakage | Cystic stump / fistula repair failure | |
| Bile duct stricture (most common long-term) | Scarring at repair / anastomosis site | |
| Anastomotic stricture (after Roux-en-Y) | Fibrosis at hepaticojejunostomy |
High Yield Summary
Complications of Mirizzi syndrome can be grouped as disease-related, systemic, and treatment-related:
Disease-related (the most important):
- Cholecystobiliary fistula (Csendes II–IV) — chronic pressure necrosis of bile duct wall
- CA gallbladder (5–28%) — chronic inflammation → dysplasia-carcinoma sequence. Always exclude with CT + MRCP + intraoperative frozen section.
- Choledocholithiasis — stones migrate through fistula into CBD. Always perform ECBD in fistula types.
- Gallstone ileus (Type V) — cholecystoenteric fistula → stone impacts at terminal ileum → SBO. Rigler's triad on AXR. Treat with enterolithotomy.
- Acute cholangitis (Charcot's/Reynolds') — bile stasis → infection
- Acute cholecystitis (1/3 of presentations)
- Acute pancreatitis (rare)
Systemic effects of obstructive jaundice: Coagulopathy (↓ Vit K), immunocompromise (impaired Kupffer cells), poor wound healing (↓ protein synthesis), renal impairment
Treatment-related:
- ERCP: Post-ERCP pancreatitis (MC, ~2%), bleeding, perforation, cholangitis
- Surgery: Bile duct injury (most feared — distorted anatomy from dense inflammation), biliary leakage, bile duct stricture (most common long-term complication), anastomotic stricture after Roux-en-Y
Active Recall - Complications of Mirizzi Syndrome
References
[1] Senior notes: felixlai.md (Mirizzi syndrome overview, classification, treatment, pp. 572–575) [2] Senior notes: maxim.md (Mirizzi syndrome definition, classification, management, gallstone ileus, pp. 131–132) [3] Lecture slides: Malignant biliary obstruction.pdf (Manifestations of pathophysiological disturbance of MBO: bleeding tendency, infection, poor wound healing) [6] Senior notes: maxim.md (Acute calculous cholecystitis pathogenesis and complications, p. 131) [7] Senior notes: felixlai.md (Acute cholangitis clinical manifestation — Charcot's/Reynolds', p. 521) [16] Senior notes: maxim.md (Acute cholangitis management — RAD; long-term complications after LC, pp. 135–136) [17] Lecture slides: GC 200. RUQ pain, jaundice and fever Cholecytitis and cholangitis Imaging of GI system.pdf (ERCP complications — perforation, bleeding from papillotomy, pancreatitis, p. 14) [21] Senior notes: maxim.md (Cholecystectomy complications — immediate, early, late, pp. 133–134) [23] Senior notes: felixlai.md (ERCP complications table, p. 89) [24] Senior notes: felixlai.md (Complications of gallstones — in gallbladder, bile duct, perforation to other sites, pp. 518–519) [25] Senior notes: felixlai.md (Roux-en-Y hepatojejunostomy — most frequent long-term complication is anastomotic stenosis, p. 543)
High Yield Summary
Definition: CHD obstruction by extrinsic compression from a stone impacted in Hartmann's pouch / cystic duct ± cholecystobiliary fistula.
Epidemiology: 0.05–4% of patients undergoing cholecystectomy; F > M (reflects gallstone epidemiology).
Risk factors: Same as gallstones (5Fs) + anatomical factors (low cystic duct insertion, long parallel cystic duct, large stones).
Key anatomy: Hartmann's pouch (infundibulum) sits adjacent to the CHD — the proximity is the anatomical basis for extrinsic compression.
Pathophysiology sequence: Large stone impacts in Hartmann's pouch → extrinsic CHD compression → obstructive jaundice + bile stasis → chronic inflammation → pressure necrosis of bile duct wall → cholecystobiliary fistula (Types II–IV) → ± cholecystoenteric fistula (Type V).
Csendes classification: Type I (no fistula), Type II ( < 1/3 CBD wall), Type III (1/3–2/3), Type IV ( > 2/3 / complete destruction), Type V (any + cholecystoenteric fistula ± gallstone ileus).
Clinical features: Jaundice + RUQ pain + fever (Charcot's triad); exception to Courvoisier's Law (palpable GB with jaundice from stones); tea-coloured urine, pale stools, pruritus.
Associations: Gallbladder carcinoma (5–28%), gallstone ileus (Type V), concurrent acute cholecystitis (1/3 of cases).
Systemic effects of obstruction: Bleeding tendency (Vit K malabsorption), biliary sepsis (impaired Kupffer cell function), poor wound healing (impaired protein synthesis).
High Yield Summary
Mirizzi syndrome DDx — key principles:
-
Mirizzi is an extramural cause of obstructive jaundice — classified with pancreatic head CA and lymphadenopathy, NOT with intraluminal stones [4]
-
Most commonly confused with choledocholithiasis — the key USG differentiator is: in Mirizzi, intrahepatic ducts are dilated but CBD is normal-calibre below the GB neck; in choledocholithiasis, the CBD itself is dilated [1]
-
Acute cholecystitis with disproportionate jaundice should trigger suspicion for Mirizzi [8]
-
Always rule out CA gallbladder with CT (5–28% coexistence rate) and MRCP (T2 differentiates inflammatory from neoplastic mass) [1]
-
Listed DDx from senior notes [1]: Choledocholithiasis, Acute cholecystitis, Liver abscess, Infected choledochal cysts, Biliary leaks, Acute pancreatitis, Acute appendicitis, RPC
-
In Hong Kong, RPC and parasitic-related biliary disease are particularly important differentials [11]
-
Painless progressive obstructive jaundice in elderly = malignant biliary obstruction until proven otherwise [4]
High Yield Summary
Diagnostic criteria: No formal criteria exist. Diagnosis is based on clinical suspicion + imaging confirmation of (1) stone at GB neck, (2) CHD obstruction at that level, (3) exclusion of malignancy, (4) assessment of cholecystobiliary fistula.
First-line investigation: USG abdomen — look for the signature triad: stone at GB neck + dilated IHD above + normal CBD below.
CT abdomen + contrast: Essential to rule out malignancy (porta hepatis LN, liver invasion).
MRCP: High sensitivity, non-invasive, differentiates inflammatory from neoplastic mass on T2-weighted images — something USG and CT cannot reliably do.
ERCP: Both diagnostic and therapeutic — confirms cholecystobiliary fistula (contrast passes from CBD into GB), determines Csendes type, and enables sphincterotomy + biliary stenting for temporary decompression.
Blood tests: Cholestatic LFT pattern (↑ ALP, ↑ conjugated bilirubin, ↑ GGT), leukocytosis, prolonged PT (correct with vitamin K before intervention).
Most cases diagnosed intraoperatively — preoperative diagnosis rate only 8–27%.
High Yield Summary
Management framework: RAD (Resuscitate → Antibiotics → Drainage) for acute presentation → Preoperative optimisation → Definitive surgery based on Csendes type.
ERCP role: Temporary biliary decompression (sphincterotomy + stenting) [1] — NOT definitive treatment. Hierarchy: ERCP → PTBD → ECBD [7].
Surgical management by type:
- Type I (no fistula): Cholecystectomy (lap or open); ECBD NOT required [1]
- Type II ( < 1/3): Cholecystectomy + fistula closure (suture/T-tube/choledochoplasty) [1]
- Type III (1/3–2/3): Cholecystectomy OR bilioenteric anastomosis; suture NOT required [1]
- Type IV ( > 2/3): Bilioenteric anastomosis (choledochojejunostomy) [1]
- Type V: Address gallstone ileus (enterolithotomy) if present + manage biliary fistula per type [2]
Key principles:
- ECBD in all fistula types to rule out CBD stones unless done endoscopically [1]
- Types II–V: open surgery with subtotal cholecystectomy (Calot's triangle too inflamed for safe dissection) [2]
- Critical View of Safety often unachievable → low threshold to convert to open [20][21]
- Always send gallbladder for histology — rule out concurrent CA gallbladder
High Yield Summary
Complications of Mirizzi syndrome can be grouped as disease-related, systemic, and treatment-related:
Disease-related (the most important):
- Cholecystobiliary fistula (Csendes II–IV) — chronic pressure necrosis of bile duct wall
- CA gallbladder (5–28%) — chronic inflammation → dysplasia-carcinoma sequence. Always exclude with CT + MRCP + intraoperative frozen section.
- Choledocholithiasis — stones migrate through fistula into CBD. Always perform ECBD in fistula types.
- Gallstone ileus (Type V) — cholecystoenteric fistula → stone impacts at terminal ileum → SBO. Rigler's triad on AXR. Treat with enterolithotomy.
- Acute cholangitis (Charcot's/Reynolds') — bile stasis → infection
- Acute cholecystitis (1/3 of presentations)
- Acute pancreatitis (rare)
Systemic effects of obstructive jaundice: Coagulopathy (↓ Vit K), immunocompromise (impaired Kupffer cells), poor wound healing (↓ protein synthesis), renal impairment
Treatment-related:
- ERCP: Post-ERCP pancreatitis (MC, ~2%), bleeding, perforation, cholangitis
- Surgery: Bile duct injury (most feared — distorted anatomy from dense inflammation), biliary leakage, bile duct stricture (most common long-term complication), anastomotic stricture after Roux-en-Y
Malignant Biliary Obstruction
Malignant biliary obstruction is the blockage of bile duct flow caused by cancerous tumors—most commonly pancreatic, cholangiocarcinoma, or ampullary neoplasms—leading to obstructive jaundice and cholestasis.
Pancreatic Cancer
Pancreatic cancer is a highly aggressive malignancy most commonly arising from the exocrine ductal epithelium of the pancreas, often presenting late with obstructive jaundice, weight loss, and pain, carrying a poor prognosis.